This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Acute myeloid leukaemia, helper endpoint
HLP_C3_AML
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
509 |
4. Check minimum number of eventsNone |
509 |
5. Include endpointsNone |
509 |
6. Filter based on genotype QC (FinnGen only) |
470 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Acute myeloid leukaemia, helper endpoint
based on the number of shared cases.
Similar with more cases:
- Acute myeloid leukaemia, including Hilmo
- Acute myeloid leukaemia
- Acute myeloid leukaemia and myelodysplastic syndromes
- Liquid cancers
- Liquid cancers, including Hilmo
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 470 | 200 | 270 |
| Unadjusted period prevalence (%) | 0.10 | 0.07 | 0.12 |
| Median age at first event (years) | 68.47 | 65.09 | 70.98 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 509
- Matched controls
- 5090
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
A04AA01
ATC
ondansetron; systemic, rectal
57.9
317.3
188
51
9861/3-C42.1
ICD-O-3
Acute myeloid leukemia, NOS, of bone marrow
+∞
307.7
344
*
WW500
NOMESCO Finland
Blood transfusion
87.5
307.7
202
38
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
6849.1
307.7
373
*
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
+∞
307.7
457
*
XW000
NOMESCO Finland
Bone marrow biopsy
148.5
307.7
308
52
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
53.3
236.7
140
36
127
Kela drug reimbursment
Transplant complication
73.7
166.8
91
15
A05AA02
ATC
ursodeoxycholic acid; oral
54.3
148.6
86
19
Z51.5
ICD-10 Finland
Palliative care
15.1
137.9
137
121
L03AA02
ATC
filgrastim; parenteral
1597.8
131.3
122
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
8.8
116.3
189
320
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
13.2
111.3
118
114
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
1073.5
94.0
89
*
H02AB02
ATC
dexamethasone; systemic
38.4
92.6
58
17
JN4AD
NOMESCO Finland
Body CT examination
9.9
88.0
114
144
ZX112
NOMESCO Finland
Subcutaneous
42.1
86.9
53
14
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
7.2
85.5
159
303
J05AB11
ATC
valaciclovir; oral
6.5
84.9
182
399
C95.0
ICD-10 Finland
Acute leukaemia of unspecified cell type
+∞
84.8
79
*
R50.9
ICD-10 Finland
Fever, unspecified
6.3
83.0
185
420
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
42.5
82.2
50
13
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
902.6
80.7
77
*
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
20.4
79.8
63
35
M04AA01
ATC
allopurinol; systemic
5.9
77.9
193
480
J01MA12
ATC
levofloxacin; systemic
5.5
74.2
204
553
L04AD01
ATC
ciclosporin; systemic
29.1
73.4
50
19
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
8.8
71.3
100
138
JN4BD
NOMESCO Finland
Extensive body CT
10.1
68.2
84
98
ZX120
NOMESCO Finland
Intravenous
8.0
67.2
102
154
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
714.7
65.4
63
*
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
14.3
65.2
62
49
J02AC03
ATC
voriconazole; systemic
361.7
63.9
63
*
D64.9
ICD-10 Finland
Anaemia, unspecified
5.5
63.9
157
381
L01XX05
ATC
hydroxycarbamide; oral
637.7
58.9
57
*
L01BB02
ATC
mercaptopurine; oral
28.9
58.7
40
15
D46.9
ICD-10 Finland
Myelodysplastic syndrome, unspecified
321.4
57.5
57
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
8.0
56.4
84
123
D70.89
ICD-10 Finland
Neutropenic splenomegaly
111.0
55.1
59
6
N02AA05
ATC
oxycodone; systemic
4.6
54.2
172
508
A04AA02
ATC
granisetron; systemic, transdermal
550.4
51.4
50
*
A03FA01
ATC
metoclopramide; systemic, rectal
4.9
49.4
135
352
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
48.7
46
*
D46.2
ICD-10 Finland
Refractory anaemia with excess of blasts [RAEB]
+∞
46.6
44
*
A41.9
ICD-10 Finland
Sepsis, unspecified
7.8
45.6
68
99
121
Kela drug reimbursment
Severe hypofunction of sexual glands
16.8
45.6
39
25
TPX10
NOMESCO Finland
Implantation of vascular injection port
13.7
44.9
43
34
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
465.6
43.9
43
*
D46.7
ICD-10 Finland
Other myelodysplastic syndromes
228.3
41.5
42
*
TGC00
NOMESCO Finland
Bronchial lavation
9.5
40.3
50
58
WW200
NOMESCO Finland
Immunization
10.4
40.1
46
48
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
70.3
39.8
45
7
B73
ICPC
Leukaemia
+∞
39.1
37
*
J01MA14
ATC
moxifloxacin; systemic
4.9
39.0
99
240
399
Kela drug reimbursment
Venetoclax
+∞
38.0
36
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
36.9
35
*
9891/3-C42.1
ICD-O-3
Acute monocytic leukemia of bone marrow
+∞
35.9
34
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
35.9
34
*
1518, ,
Kela drug reimbursment
+∞
35.9
34
*
B03XA02
ATC
darbepoetin alfa; parenteral
12.4
35.5
36
31
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.6
35.3
156
563
L03AA13
ATC
pegfilgrastim; parenteral
193.3
35.2
36
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
34.7
320
1773
L04AA06
ATC
mycophenolic acid; systemic
12.9
34.5
34
28
C61
ICD-10 Finland
Malignant neoplasm of prostate
360.1
34.3
34
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
360.1
34.3
34
*
WZC00
NOMESCO Finland
Treatment plan or consultation
3.2
34.1
197
835
J02AC04
ATC
posaconazole; systemic
+∞
33.7
32
*
WW306
NOMESCO Finland
Transfer of stem cells from foreign registered donator
+∞
33.7
32
*
L01XX52
ATC
venetoclax; oral
+∞
33.7
32
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
6.5
33.4
58
99
C92.5
ICD-10 Finland
Acute myelomonocytic leukaemia
+∞
31.6
30
*
C95.9
ICD-10 Finland
Leukaemia, unspecified
+∞
30.5
29
*
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
+∞
30.5
29
*
Y84.8
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
34.1
29.5
38
12
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
+∞
29.5
28
*
C92.4
ICD-10 Finland
Acute promyelocytic leukaemia [PML]
+∞
28.4
27
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
6.1
27.5
50
89
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
6.2
27.3
49
86
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
79.7
27.1
30
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.7
26.7
67
159
212
Kela drug reimbursment
Gout
7.8
26.6
38
52
WW302
NOMESCO Finland
Allogenic transfer of stem cells from relative
+∞
26.3
25
*
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
+∞
26.3
25
*
115
Kela drug reimbursment
Breast cancer
+∞
26.3
25
*
J05AB01
ATC
aciclovir; systemic
3.0
26.2
149
613
H02AB09
ATC
hydrocortisone; systemic
8.9
25.1
32
38
GD1AD
NOMESCO Finland
Thorax CT examination
4.9
25.0
58
129
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
10.5
24.9
28
28
D45
ICD-10 Finland
Polycythaemia vera
262.3
24.9
25
*
D47.3
ICD-10 Finland
Essential (haemorrhagic) thrombocythaemia
+∞
23.1
22
*
WW409
NOMESCO Finland
Other aferesis
+∞
23.1
22
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
23.1
22
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
4.3
22.9
64
165
D70.82
ICD-10 Finland
Drug-induced neutropenia
87.5
22.9
25
*
TPH00
NOMESCO Finland
Phlebotomy
125.7
22.8
24
*
2050A
ICD-9 Finland
Myeloid leukaemia, Acute
+∞
22.0
21
*
C92.9
ICD-10 Finland
Myeloid leukaemia, unspecified
+∞
22.0
21
*
9989/3-C42.1
ICD-O-3
Myelodysplastic syndrome, NOS, of bone marrow
+∞
22.0
21
*
9873/3-C42.1
ICD-O-3
Acute myeloid leukemia without maturation of bone marrow
+∞
22.0
21
*
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
35.5
21.3
27
8
JN6AD
NOMESCO Finland
CT of torso and neck
29.5
21.2
28
10
116
Kela drug reimbursment
Prostate cancer
+∞
21.0
20
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
5.4
20.6
42
83
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
50.2
20.3
24
5
D64.8
ICD-10 Finland
Other specified anaemias
8.8
20.3
26
31
QX2XE
NOMESCO Finland
Ultrsound examination of soft tissue not elsewhere classified
7.1
20.2
31
46
A41.1
ICD-10 Finland
Sepsis due to other specified staphylococcus
21.9
20.2
29
14
9961/3-C42.1
ICD-O-3
Primary myelofibrosis of bone marrow
+∞
19.9
19
*
9895/3-C42.1
ICD-O-3
Acute myeloid leukemia with myelodysplasia-related changes of bone marrow
+∞
19.9
19
*
WD515
NOMESCO Finland
Demanding therapy of malignancy with enzyme inhibitors and similar treatments
+∞
19.9
19
*
9920/3-C42.1
ICD-O-3
Therapy-related myeloid neoplasm of bone marrow
+∞
19.9
19
*
A41.8
ICD-10 Finland
Other specified sepsis
8.1
19.7
27
35
C90.0
ICD-10 Finland
Multiple myeloma
207.7
19.7
20
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.8
18.9
62
179
9950/3-C42.1
ICD-O-3
Polycythemia vera of bone marrow
+∞
18.9
18
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
72.7
18.8
21
*
J02AC01
ATC
fluconazole; systemic
2.4
18.8
200
1094
WF002
NOMESCO Finland
Radical radiotherapy
103.9
18.7
20
*
ZX121
NOMESCO Finland
Central venous catheter
197.0
18.7
19
*
L02AE02
ATC
leuprorelin; implant, parenteral
69.2
17.8
20
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
17.8
17
*
8090/3-C44.3
ICD-O-3
Basal cell carcinoma, NOS, of skin of other and unspecified parts of face
+∞
17.8
17
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
17.8
17
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
186.2
17.6
18
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
3.7
17.6
59
173
L04AD02
ATC
tacrolimus; systemic
30.0
17.6
23
8
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.3
17.5
199
1113
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
5.5
17.3
34
65
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
14.7
17.0
28
20
JN3AD
NOMESCO Finland
Abdominal CT examination
3.1
16.9
81
297
ZX090
NOMESCO Finland
Other technic of radiotherapy
65.6
16.8
19
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
+∞
16.8
16
*
9874/3-C42.1
ICD-O-3
Acute myeloid leukemia with maturation of bone marrow
+∞
16.8
16
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
+∞
16.8
16
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
16.8
16
*
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.0
16.6
82
306
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.2
16.5
198
1125
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
6.1
16.4
29
50
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
5.5
16.3
32
61
B02AA02
ATC
tranexamic acid; systemic
3.0
15.7
79
297
C93.0
ICD-10 Finland
Acute monoblastic/monocytic leukaemia
+∞
15.7
15
*
1DB06, ,
NOMESCO Finland
+∞
15.7
15
*
HAC20
NOMESCO Finland
Total mastectomy
+∞
15.7
15
*
9983/3-C42.1
ICD-O-3
Myelodysplastic syndrome with excess blasts of bone marrow
+∞
15.7
15
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.3
15.6
167
902
WD505
NOMESCO Finland
Simple enzyme inhibitor or similar therapy of methastized malignancy
164.9
15.6
16
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
15.2
134
665
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
4.9
15.2
34
73
SPAT1088
SPAT
Blood transfusion
32.8
14.9
19
6
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
58.5
14.9
17
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
14.7
14
*
130
Kela drug reimbursment
Malignant tumour
+∞
14.7
14
*
J05AX18
ATC
letermovir; oral
+∞
14.7
14
*
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
154.2
14.5
15
*
XX3DW
NOMESCO Finland
Time consuming IT work
4.4
14.4
37
89
HA1AA
NOMESCO Finland
X-ray mammography
5.3
13.8
28
55
9867/3-C42.1
ICD-O-3
Acute myelomonocytic leukemia, NOS, of bone marrow
+∞
13.6
13
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
13.6
13
*
L03AB05
ATC
interferon alfa-2b; parenteral
+∞
13.6
13
*
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
35.1
13.6
17
5
L04AA01
ATC
[U] ciclosporin
16.8
13.6
21
13
TAB00
NOMESCO Finland
Lumbar puncture
4.2
13.4
37
94
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
6.5
13.4
22
35
L02BG04
ATC
letrozole; oral
29.2
13.0
17
6
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.2
12.7
53
178
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
12.5
12
*
WW304
NOMESCO Finland
Transfer of stem cells from registered domestic donator
+∞
12.5
12
*
1BC07, ,
NOMESCO Finland
+∞
12.5
12
*
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
+∞
12.5
12
*
9866/3-C42.1
ICD-O-3
Acute promyelocytic leukemia, t(15;17)(q22;q11-12) of bone marrow
+∞
12.5
12
*
A79
ICPC
Malignancy NOS
+∞
12.5
12
*
J02AC05
ATC
isavuconazole; systemic
+∞
12.5
12
*
L02BA01
ATC
tamoxifen; oral
133.2
12.5
13
*
Y77
ICPC
Malignant neoplasm prostate
133.2
12.5
13
*
306
Kela drug reimbursment
Erythropoietin and darbepoetin
133.2
12.5
13
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
2.8
12.2
67
263
H02AB06
ATC
prednisolone; systemic
1.9
12.1
255
1734
JN4CD
NOMESCO Finland
Very extensive body CT
10.0
11.9
23
24
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.5
11.6
80
352
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
11.5
11
*
2AX04, ,
NOMESCO Finland
+∞
11.5
11
*
C92.3
ICD-10 Finland
Myeloid sarcoma
+∞
11.5
11
*
9962/3-C42.1
ICD-O-3
Essential thrombocythemia of bone marrow
+∞
11.5
11
*
TNE20
NOMESCO Finland
Bone marrow aspiration, pelvis
122.7
11.5
12
*
EB1CI
NOMESCO Finland
Cone beam imaging of teeth and jaws (3-4 quarters)
17.5
11.3
17
10
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.9
10.8
206
1340
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
4.7
10.8
25
55
B03XA01
ATC
erythropoietin; parenteral
18.3
10.8
16
9
B01AB05
ATC
enoxaparin; parenteral
2.0
10.7
162
976
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
61.3
10.7
12
*
B25.9
ICD-10 Finland
Cytomegaloviral disease, unspecified
61.3
10.7
12
*
ZXD05
NOMESCO Finland
Urgent procedure
2.0
10.6
159
954
A40.8
ICD-10 Finland
Other streptococcal sepsis
10.4
10.6
20
20
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
112.2
10.5
11
*
Z85.6
ICD-10 Finland
Personal history of leukaemia
+∞
10.4
10
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
10.4
10
*
XW4XT
NOMESCO Finland
Biopsy of other inner organ with radiological guidance guidance
+∞
10.4
10
*
1DB07, ,
NOMESCO Finland
+∞
10.4
10
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
10.4
10
*
L02BB03
ATC
bicalutamide; oral
+∞
10.4
10
*
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
23.9
10.3
14
6
A02BC02
ATC
pantoprazole; systemic
1.9
10.1
338
2608
D75.2
ICD-10 Finland
Essential thrombocytosis
40.9
10.0
12
*
NK6AN
NOMESCO Finland
Total body bone isotope imaging
40.9
10.0
12
*
J01MA02
ATC
ciprofloxacin; systemic
1.8
10.0
212
1420
H02AB04
ATC
methylprednisolone; systemic
2.2
9.9
90
446
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
5.1
9.9
21
43
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
26.6
9.9
13
5
D46.3
ICD-10 Finland
Refractory anemia with excess of blasts with transformation
56.1
9.7
11
*
N05BA06
ATC
lorazepam; systemic, sublingual
3.0
9.6
43
151
D11AH01
ATC
tacrolimus; topical
15.4
9.6
15
10
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
101.9
9.4
10
*
WVA30
NOMESCO Finland
Intramuscular and subcutaneous injection
30.7
9.4
12
*
A49.8
ICD-10 Finland
Other bacterial infections of unspecified site
12.7
9.4
16
13
D46.0
ICD-10 Finland
Refractory anaemia without ring sideroblasts, so stated
+∞
9.4
9
*
C85.9
ICD-10 Finland
Non-Hodgkin lymphoma, unspecified
+∞
9.4
9
*
174
Kela drug reimbursment
Ruxolitinib
+∞
9.4
9
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
9.4
9
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
9.4
9
*
C50.99
ICD-10 Finland
Breast, unspecified
+∞
9.4
9
*
8090/3-C44.5
ICD-O-3
Basal cell carcinoma, NOS, of skin of trunk
+∞
9.4
9
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
9.4
9
*
SPAT1074
SPAT
Venesection
37.4
9.0
11
*
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.8
9.0
249
1790
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.6
9.0
53
216
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
50.9
8.7
10
*
D72.9
ICD-10 Finland
Disorder of white blood cells, unspecified
50.9
8.7
10
*
ZXE00
NOMESCO Finland
One hour or less
1.8
8.6
187
1248
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
10.3
8.6
16
16
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
+∞
8.4
8
*
9872/3-C42.1
ICD-O-3
Acute myeloid leukemia, minimal differentiation of bone marrow
+∞
8.4
8
*
374
Kela drug reimbursment
Ruxolitinib
+∞
8.4
8
*
A04AD12
ATC
aprepitant; systemic
+∞
8.4
8
*
128
Kela drug reimbursment
Cancers of female genital organs
+∞
8.4
8
*
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
+∞
8.4
8
*
C44.32
ICD-10 Finland
Spinocellular carcinoma of the skin on another or unspecified part of the face
+∞
8.4
8
*
B74
ICPC
Malignant neoplasm blood other
+∞
8.4
8
*
A07AA09
ATC
vancomycin; oral
9.7
8.3
16
17
R4110
NOMESCO Finland
Physiotherapy
1.9
8.1
135
828
WW200, ,
SPAT
0.4
8.0
54
1095
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
2.8
7.9
40
150
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
3.8
7.7
23
62
B99
ICD-10 Finland
Other and unspecified infectious diseases
4.6
7.7
18
40
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
18.7
7.6
11
6
5BA08, ,
NOMESCO Finland
18.7
7.6
11
6
QBA25
NOMESCO Finland
Destruction of lesion of skin of trunk
18.7
7.6
11
6
D48.5
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Skin
3.1
7.6
31
103
R72
ICD-10 Finland
Abnormality of white blood cells, not elsewhere classified
25.4
7.6
10
*
J17.3*B59
ICD-10 Finland
Pneumonia due to Pneumocystis carinii
25.4
7.6
10
*
A07AA02
ATC
nystatin; oral
2.8
7.5
38
143
JN6DR
NOMESCO Finland
PET-CT of whole body metabolism
13.6
7.4
12
9
C50.11
ICD-10 Finland
Malignant tumor of the central part of the mammary gland,ductal tumor
+∞
7.3
7
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
7.3
7
*
9945/3-C42.1
ICD-O-3
Chronic myelomonocytic leukemia, NOS, of bone marrow
+∞
7.3
7
*
20500
ICD-8 Finland
Myeloid leukaemia, Acute
+∞
7.3
7
*
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
+∞
7.3
7
*
HA013
NOMESCO Finland
Radiotherapy after total ablation of mammary gland
+∞
7.3
7
*
D89.89
ICD-10 Finland
Other specified disorders involving the immune mechanism, not elsewhere classified
+∞
7.3
7
*
N05AX08
ATC
risperidone; systemic
0.2
7.3
8
362
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
30.5
7.2
9
*
A98
ICPC
Health maint/preventive medicine
0.6
6.9
363
4134
Z3231
NOMESCO Finland
Registered nurse
1.8
6.9
131
833
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
4.2
6.9
18
44
Z76.0
ICD-10 Finland
Issue of repeat prescription
0.4
6.9
40
864
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
6.2
6.8
17
28
D61.9
ICD-10 Finland
Aplastic anaemia, unspecified
40.6
6.8
8
*
M87.1
ICD-10 Finland
Osteonecrosis due to drugs
40.6
6.8
8
*
ED1AA
NOMESCO Finland
Mandibular X-ray examination
40.6
6.8
8
*
TPX15
NOMESCO Finland
Removal of vascular injection port
40.6
6.8
8
*
WVA20
NOMESCO Finland
Medicine administration
4.0
6.8
19
49
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
17.0
6.8
10
6
G30.1
ICD-10 Finland
Alzheimer disease with late onset
0.2
6.7
7
327
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
4.1
6.7
18
45
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
10.2
6.6
12
12
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
2.8
6.5
33
124
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
2.4
6.5
43
185
L02BG06
ATC
exemestane; oral
70.7
6.4
7
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
70.7
6.4
7
*
WZC30
NOMESCO Finland
Teaching
2.1
6.4
64
328
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.7
6.4
147
983
ZX100
NOMESCO Finland
Oral
6.7
6.4
15
23
J01FF01
ATC
clindamycin; systemic
1.7
6.3
133
869
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
2.9
6.3
29
104
T86.9
ICD-10 Finland
Failure and rejection of unspecified transplanted organ and tissue
+∞
6.3
6
*
D61.0
ICD-10 Finland
Constitutional aplastic anaemia
+∞
6.3
6
*
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
+∞
6.3
6
*
WB121
NOMESCO Finland
Demanding neoadjuvant cytostatic therapy
+∞
6.3
6
*
C92
ICD-10 Finland
Myeloid leukaemia
+∞
6.3
6
*
C50.90
ICD-10 Finland
Malignant tumor in other or unspecified location in mammary gland without histology
+∞
6.3
6
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
6.3
6
*
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
+∞
6.3
6
*
D46.1
ICD-10 Finland
Refractory anaemia with ring sideroblasts
+∞
6.3
6
*
E89.4
ICD-10 Finland
Postprocedural ovarian failure
+∞
6.3
6
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
6.3
6
*
C92.2
ICD-10 Finland
Atypical chronic myeloid leukaemia, BCR/ABL- negative
+∞
6.3
6
*
C44.61
ICD-10 Finland
Basocellular carcinoma of the skin of the upper extremity including the shoulder
+∞
6.3
6
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
6.3
6
*
C64.88
ICD-10 Finland
Other malignant neoplasm of kidney, except renal pelvis
+∞
6.3
6
*
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
6.3
6
*
L03AB04
ATC
interferon alfa-2a; parenteral
+∞
6.3
6
*
6BA02, ,
NOMESCO Finland
+∞
6.3
6
*
C92.7
ICD-10 Finland
Other myeloid leukaemia
+∞
6.3
6
*
C54.11
ICD-10 Finland
Adenocarcinoma of the endometrium
+∞
6.3
6
*
A02BC01
ATC
omeprazole; systemic
1.7
6.3
142
946
JN6BD
NOMESCO Finland
Extensive CT of torso and neck
27.0
6.2
8
*
HA1AT
NOMESCO Finland
Biopsy of mammary glands with ultrasound guidance
27.0
6.2
8
*
N05CF01
ATC
zopiclone; oral
1.6
6.2
171
1198
D07AB08
ATC
desonide; topical
2.1
6.2
58
290
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
2.5
6.1
38
159
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
1.2e+00
2.5e+00
5.6e+00
1.0e+50
5.5e+00
4.5e+00
3.2e+00
cases:5.21%
controls:1.65%
cases:9.38%
controls:0.86%
cases:22.16%
controls:0.10%
cases:20.36%
controls:0.00%
cases:33.77%
controls:0.20%
cases:41.46%
controls:0.79%
cases:39.23%
controls:2.57%
26
82
473
4883
47
43
454
4932
111
5
390
4970
102
0
399
4975
153
10
300
4958
148
39
209
4868
82
105
127
3981
Hematology
82 [38004501]
82 [38004501]
2.7e+00
4.1e+00
—
1.0e+50
—
7.2e+00
6.5e+00
cases:7.41%
controls:0.54%
cases:12.97%
controls:0.24%
—
—
cases:22.16%
controls:0.00%
—
—
cases:78.99%
controls:0.29%
cases:80.38%
controls:0.59%
37
27
462
4938
65
12
436
4963
—
111
0
390
4975
—
282
14
75
4893
168
24
41
4062
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
14196-0 [3023520]
1.1e+00
2.1e+00
—
1.0e+50
5.5e+00
4.0e+00
2.5e+00
cases:4.21%
controls:1.43%
cases:5.99%
controls:0.80%
—
—
cases:18.36%
controls:0.00%
cases:19.65%
controls:0.10%
cases:29.69%
controls:0.75%
cases:23.92%
controls:2.55%
21
71
478
4894
30
40
471
4935
—
92
0
409
4975
89
5
364
4963
106
37
251
4870
50
104
159
3982
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
26498-6 [3017181]
1.5e+00
2.3e+00
5.1e+00
1.0e+50
—
3.8e+00
2.1e+00
cases:3.41%
controls:0.77%
cases:6.19%
controls:0.66%
cases:14.77%
controls:0.10%
cases:12.97%
controls:0.00%
—
—
cases:24.09%
controls:0.67%
cases:19.62%
controls:2.79%
17
38
482
4927
31
33
470
4942
74
5
427
4970
65
0
436
4975
—
86
33
271
4874
41
114
168
3972
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
1.0e+00
1.3e+00
3.0e+00
1.0e+50
3.9e+00
3.8e+00
3.1e+00
cases:3.01%
controls:1.09%
cases:1.60%
controls:0.42%
cases:3.19%
controls:0.16%
cases:1.00%
controls:0.00%
cases:4.86%
controls:0.10%
cases:15.97%
controls:0.41%
cases:14.35%
controls:0.73%
15
54
484
4911
8
21
493
4954
16
8
485
4967
5
0
496
4975
22
5
431
4963
57
20
300
4887
30
30
179
4056
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
4679-7 [3027945]
7.8e-01
1.9e+00
—
1.0e+50
5.6e+00
3.9e+00
2.4e+00
cases:5.21%
controls:2.46%
cases:7.19%
controls:1.17%
—
—
cases:20.16%
controls:0.00%
cases:21.85%
controls:0.10%
cases:32.21%
controls:0.98%
cases:26.79%
controls:3.26%
26
122
473
4843
36
58
465
4917
—
101
0
400
4975
99
5
354
4963
115
48
242
4859
56
133
153
3953
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
14933-6 [3026493]
2.5e-01
8.5e-01
3.9e+00
—
5.2e+00
3.0e+00
1.5e+00
cases:8.02%
controls:6.38%
cases:5.99%
controls:2.65%
cases:14.17%
controls:0.32%
—
—
cases:30.24%
controls:0.24%
cases:35.01%
controls:2.71%
cases:26.32%
controls:7.22%
40
317
459
4648
30
132
471
4843
71
16
430
4959
—
137
12
316
4956
125
133
232
4774
55
295
154
3791
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
6.4e-01
1.2e+00
3.9e+00
—
4.3e+00
2.7e+00
1.6e+00
cases:17.43%
controls:10.01%
cases:14.97%
controls:5.05%
cases:25.15%
controls:0.66%
—
—
cases:34.88%
controls:0.74%
cases:44.26%
controls:5.26%
cases:43.54%
controls:13.49%
87
497
412
4468
75
251
426
4724
126
33
375
4942
—
158
37
295
4931
158
258
199
4649
91
551
118
3535
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
GD1UA [2001303652]
3.3e-01
1.8e+00
3.7e+00
1.0e+50
4.2e+00
3.2e+00
1.2e+00
cases:3.21%
controls:2.34%
cases:2.59%
controls:0.42%
cases:3.99%
controls:0.10%
cases:2.40%
controls:0.00%
cases:6.40%
controls:0.10%
cases:14.85%
controls:0.67%
cases:8.61%
controls:2.67%
16
116
483
4849
13
21
488
4954
20
5
481
4970
12
0
489
4975
29
5
424
4963
53
33
304
4874
18
109
191
3977
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
4.3e-01
8.3e-01
4.2e+00
1.0e+50
5.0e+00
3.0e+00
1.3e+00
cases:7.41%
controls:4.95%
cases:4.79%
controls:2.15%
cases:17.37%
controls:0.32%
cases:7.39%
controls:0.00%
cases:28.04%
controls:0.26%
cases:35.01%
controls:2.71%
cases:23.44%
controls:7.83%
37
246
462
4719
24
107
477
4868
87
16
414
4959
37
0
464
4975
127
13
326
4955
125
133
232
4774
49
320
160
3766
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
77397-8 [46236098]
6.6e-01
9.1e-01
3.9e+00
—
4.8e+00
2.9e+00
1.1e+00
cases:7.21%
controls:3.87%
cases:4.39%
controls:1.81%
cases:8.38%
controls:0.18%
—
—
cases:18.98%
controls:0.20%
cases:24.65%
controls:1.79%
cases:13.40%
controls:4.97%
36
192
463
4773
22
90
479
4885
42
9
459
4966
—
86
10
367
4958
88
88
269
4819
28
203
181
3883
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
34487-9 [3044938]
6.7e-01
7.3e-01
4.6e+00
1.0e+50
4.6e+00
3.3e+00
1.7e+00
cases:3.41%
controls:1.77%
cases:2.40%
controls:1.17%
cases:10.38%
controls:0.12%
cases:3.19%
controls:0.00%
cases:13.91%
controls:0.16%
cases:29.13%
controls:1.55%
cases:22.01%
controls:5.07%
17
88
482
4877
12
58
489
4917
52
6
449
4969
16
0
485
4975
63
8
390
4960
104
76
253
4831
46
207
163
3879
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
5.8e-01
1.3e+00
3.7e+00
—
3.8e+00
2.7e+00
2.0e+00
cases:12.02%
controls:7.13%
cases:14.37%
controls:4.46%
cases:26.55%
controls:0.90%
—
—
cases:31.79%
controls:0.99%
cases:39.50%
controls:4.28%
cases:41.63%
controls:8.96%
60
354
439
4611
72
222
429
4753
133
45
368
4930
—
144
49
309
4919
141
210
216
4697
87
366
122
3720
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
57782-5 [40760892]
6.4e-01
1.6e+00
3.7e+00
1.0e+50
4.0e+00
2.5e+00
1.5e+00
cases:7.21%
controls:3.95%
cases:9.58%
controls:2.17%
cases:14.17%
controls:0.40%
cases:9.58%
controls:0.00%
cases:15.01%
controls:0.32%
cases:21.85%
controls:2.18%
cases:22.01%
controls:5.78%
36
196
463
4769
48
108
453
4867
71
20
430
4955
48
0
453
4975
68
16
385
4952
78
107
279
4800
46
236
163
3850
Dentistry
C5 [903277]
C5 [903277]
3.3e-01
1.4e+00
2.9e+00
—
3.9e+00
3.6e+00
2.1e+00
cases:2.40%
controls:1.73%
cases:2.20%
controls:0.54%
cases:1.80%
controls:0.10%
—
—
cases:4.86%
controls:0.10%
cases:15.69%
controls:0.51%
cases:13.88%
controls:1.96%
12
86
487
4879
11
27
490
4948
9
5
492
4970
—
22
5
431
4963
56
25
301
4882
29
80
180
4006
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
26524-9 [3021440]
1.4e+00
2.2e+00
4.9e+00
1.0e+50
—
3.5e+00
1.8e+00
cases:3.01%
controls:0.75%
cases:5.59%
controls:0.66%
cases:11.58%
controls:0.10%
cases:9.98%
controls:0.00%
—
—
cases:18.49%
controls:0.65%
cases:14.83%
controls:2.69%
15
37
484
4928
28
33
473
4942
58
5
443
4970
50
0
451
4975
—
66
32
291
4875
31
110
178
3976
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
75622-1 [46235355]
5.9e-01
1.4e+00
3.5e+00
—
4.5e+00
2.9e+00
1.4e+00
cases:3.41%
controls:1.91%
cases:3.39%
controls:0.88%
cases:4.99%
controls:0.16%
—
—
cases:13.02%
controls:0.16%
cases:13.45%
controls:0.86%
cases:9.57%
controls:2.57%
17
95
482
4870
17
44
484
4931
25
8
476
4967
—
59
8
394
4960
48
42
309
4865
20
105
189
3981
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
40987-0 [3043924]
1.5e-01
7.5e-01
4.3e+00
1.0e+50
4.3e+00
3.1e+00
1.7e+00
cases:1.40%
controls:1.21%
cases:1.60%
controls:0.76%
cases:7.19%
controls:0.10%
cases:1.20%
controls:0.00%
cases:9.27%
controls:0.14%
cases:21.01%
controls:1.18%
cases:17.70%
controls:3.70%
7
60
492
4905
8
38
493
4937
36
5
465
4970
6
0
495
4975
42
7
411
4961
75
58
282
4849
37
151
172
3935
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
34531-4 [3044640]
8.2e-01
6.5e-01
3.5e+00
—
4.8e+00
3.0e+00
1.2e+00
cases:11.22%
controls:5.30%
cases:4.59%
controls:2.45%
cases:10.98%
controls:0.36%
—
—
cases:26.27%
controls:0.28%
cases:32.21%
controls:2.32%
cases:18.66%
controls:6.41%
56
263
443
4702
23
122
478
4853
55
18
446
4957
—
119
14
334
4954
115
114
242
4793
39
262
170
3824
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
6.7e-01
1.3e+00
3.4e+00
—
3.7e+00
2.6e+00
1.7e+00
cases:17.43%
controls:9.73%
cases:20.16%
controls:6.17%
cases:25.95%
controls:1.21%
—
—
cases:35.98%
controls:1.41%
cases:47.06%
controls:6.15%
cases:45.45%
controls:13.46%
87
483
412
4482
101
307
400
4668
130
60
371
4915
—
163
70
290
4898
168
302
189
4605
95
550
114
3536
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
5195-3 [3019284]
6.6e-01
1.0e+00
3.3e+00
—
5.0e+00
3.2e+00
1.8e+00
cases:2.81%
controls:1.47%
cases:2.40%
controls:0.86%
cases:3.59%
controls:0.14%
—
—
cases:13.47%
controls:0.10%
cases:14.01%
controls:0.67%
cases:9.09%
controls:1.62%
14
73
485
4892
12
43
489
4932
18
7
483
4968
—
61
5
392
4963
50
33
307
4874
19
66
190
4020
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
6.4e-01
1.3e+00
3.4e+00
—
3.6e+00
2.6e+00
1.7e+00
cases:17.03%
controls:9.77%
cases:20.16%
controls:6.15%
cases:25.55%
controls:1.19%
—
—
cases:34.00%
controls:1.39%
cases:46.78%
controls:6.15%
cases:45.45%
controls:13.41%
85
485
414
4480
101
306
400
4669
128
59
373
4916
—
154
69
299
4899
167
302
190
4605
95
548
114
3538
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
6.3e-01
1.4e+00
3.3e+00
—
3.6e+00
2.6e+00
1.7e+00
cases:16.83%
controls:9.71%
cases:20.16%
controls:6.13%
cases:25.15%
controls:1.17%
—
—
cases:33.55%
controls:1.39%
cases:46.50%
controls:6.15%
cases:45.45%
controls:13.63%
84
482
415
4483
101
305
400
4670
126
58
375
4917
—
152
69
301
4899
166
302
191
4605
95
557
114
3529
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
6.3e-01
1.3e+00
3.3e+00
—
3.6e+00
2.6e+00
1.7e+00
cases:17.03%
controls:9.83%
cases:20.36%
controls:6.25%
cases:25.35%
controls:1.29%
—
—
cases:35.54%
controls:1.43%
cases:46.50%
controls:6.34%
cases:45.93%
controls:13.88%
85
488
414
4477
102
311
399
4664
127
64
374
4911
—
161
71
292
4897
166
311
191
4596
96
567
113
3519
Blood transfusion
WW500 [2001310603]
WW500 [2001310603]
2.3e+00
—
1.0e+50
—
—
5.8e+00
4.9e+00
cases:2.00%
controls:0.20%
—
—
cases:2.59%
controls:0.00%
—
—
—
—
cases:29.97%
controls:0.12%
cases:13.88%
controls:0.12%
10
10
489
4955
—
13
0
488
4975
—
—
107
6
250
4901
29
5
180
4081
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
4.4e-01
9.0e-01
3.9e+00
—
3.9e+00
2.9e+00
1.4e+00
cases:14.03%
controls:9.51%
cases:7.98%
controls:3.40%
cases:17.17%
controls:0.42%
—
—
cases:13.25%
controls:0.32%
cases:38.38%
controls:3.24%
cases:32.06%
controls:10.33%
70
472
429
4493
40
169
461
4806
86
21
415
4954
—
60
16
393
4952
137
159
220
4748
67
422
142
3664
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
3.3e-01
3.7e-01
3.5e+00
1.0e+50
4.8e+00
3.2e+00
1.5e+00
cases:4.01%
controls:2.92%
cases:1.40%
controls:0.96%
cases:7.58%
controls:0.24%
cases:15.57%
controls:0.00%
cases:19.21%
controls:0.20%
cases:20.17%
controls:1.06%
cases:15.31%
controls:3.84%
20
145
479
4820
7
48
494
4927
38
12
463
4963
78
0
423
4975
87
10
366
4958
72
52
285
4855
32
157
177
3929
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
1.4e-01
5.1e-01
2.8e+00
5.2e+00
3.0e+00
1.4e+00
3.4e-01
cases:33.67%
controls:30.65%
cases:29.34%
controls:19.88%
cases:37.13%
controls:3.60%
cases:30.94%
controls:0.24%
cases:41.94%
controls:3.56%
cases:49.86%
controls:20.22%
cases:47.85%
controls:39.43%
168
1522
331
3443
147
989
354
3986
186
179
315
4796
155
12
346
4963
190
177
263
4791
178
992
179
3915
100
1611
109
2475
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2465-3 [3005719]
9.5e-01
1.5e+00
—
1.0e+50
4.8e+00
3.5e+00
2.8e+00
cases:2.40%
controls:0.95%
cases:2.99%
controls:0.68%
—
—
cases:8.78%
controls:0.00%
cases:11.26%
controls:0.10%
cases:15.97%
controls:0.59%
cases:20.10%
controls:1.44%
12
47
487
4918
15
34
486
4941
—
44
0
457
4975
51
5
402
4963
57
29
300
4878
42
59
167
4027
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
48065-7 [3051714]
5.1e-01
9.3e-01
3.9e+00
1.0e+50
5.4e+00
2.3e+00
6.2e-01
cases:6.21%
controls:3.83%
cases:3.79%
controls:1.53%
cases:8.18%
controls:0.18%
cases:15.37%
controls:0.00%
cases:18.32%
controls:0.10%
cases:12.32%
controls:1.32%
cases:9.09%
controls:5.12%
31
190
468
4775
19
76
482
4899
41
9
460
4966
77
0
424
4975
83
5
370
4963
44
65
313
4842
19
209
190
3877
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
4.7e-01
7.6e-01
2.8e+00
—
4.5e+00
3.5e+00
1.8e+00
cases:3.81%
controls:2.42%
cases:2.59%
controls:1.23%
cases:4.19%
controls:0.26%
—
—
cases:28.92%
controls:0.46%
cases:29.97%
controls:1.28%
cases:19.14%
controls:3.89%
19
120
480
4845
13
61
488
4914
21
13
480
4962
—
131
23
322
4945
107
63
250
4844
40
159
169
3927
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
6.2e-01
1.2e+00
3.1e+00
—
3.5e+00
2.5e+00
1.5e+00
cases:19.64%
controls:11.60%
cases:20.76%
controls:7.22%
cases:24.75%
controls:1.45%
—
—
cases:36.64%
controls:1.65%
cases:47.62%
controls:7.25%
cases:46.89%
controls:16.08%
98
576
401
4389
104
359
397
4616
124
72
377
4903
—
166
82
287
4886
170
356
187
4551
98
657
111
3429
ondansetron; oral, parenteral, rectal
A04AA01 [21600493]
A04AA01 [21600493]
2.6e+00
—
—
—
—
5.8e+00
4.0e+00
cases:1.80%
controls:0.14%
—
—
—
—
—
—
—
—
cases:29.41%
controls:0.12%
cases:17.22%
controls:0.37%
9
7
490
4958
—
—
—
—
105
6
252
4901
36
15
173
4071
Fever, unspecified
R50.9 [45582716]
R50.9 [45582716]
9.9e-01
2.0e+00
—
—
3.3e+00
3.8e+00
2.3e+00
cases:3.41%
controls:1.29%
cases:2.99%
controls:0.42%
—
—
—
—
cases:2.65%
controls:0.10%
cases:18.77%
controls:0.51%
cases:15.31%
controls:1.86%
17
64
482
4901
15
21
486
4954
—
—
12
5
441
4963
67
25
290
4882
32
76
177
4010
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
6.0e-01
3.9e-01
3.3e+00
—
4.5e+00
2.7e+00
1.1e+00
cases:13.83%
controls:8.10%
cases:5.39%
controls:3.72%
cases:14.77%
controls:0.64%
—
—
cases:30.24%
controls:0.46%
cases:35.29%
controls:3.40%
cases:24.40%
controls:9.99%
69
402
430
4563
27
185
474
4790
74
32
427
4943
—
137
23
316
4945
126
167
231
4740
51
408
158
3678
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
3.2e-01
1.0e+00
3.2e+00
—
4.2e+00
2.4e+00
1.4e+00
cases:12.22%
controls:9.20%
cases:5.59%
controls:2.09%
cases:4.59%
controls:0.20%
—
—
cases:12.14%
controls:0.20%
cases:22.13%
controls:2.53%
cases:23.92%
controls:7.20%
61
457
438
4508
28
104
473
4871
23
10
478
4965
—
55
10
398
4958
79
124
278
4783
50
294
159
3792
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
6.3e-01
1.2e+00
2.8e+00
—
3.4e+00
2.5e+00
1.6e+00
cases:16.43%
controls:9.51%
cases:18.56%
controls:6.13%
cases:17.96%
controls:1.27%
—
—
cases:29.80%
controls:1.45%
cases:44.82%
controls:6.24%
cases:43.06%
controls:13.51%
82
472
417
4493
93
305
408
4670
90
63
411
4912
—
135
72
318
4896
160
306
197
4601
90
552
119
3534
Internal Medicine
11 [38004456]
11 [38004456]
3.4e-01
1.0e+00
3.5e+00
—
3.4e+00
2.5e+00
1.4e+00
cases:32.06%
controls:25.06%
cases:22.75%
controls:9.49%
cases:33.73%
controls:1.59%
—
—
cases:30.91%
controls:1.53%
cases:56.86%
controls:10.07%
cases:54.07%
controls:23.03%
160
1244
339
3721
114
472
387
4503
169
79
332
4896
—
140
76
313
4892
203
494
154
4413
113
941
96
3145
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
5.0e-01
1.2e+00
2.9e+00
—
3.3e+00
2.4e+00
1.6e+00
cases:16.43%
controls:10.65%
cases:18.96%
controls:6.63%
cases:19.56%
controls:1.27%
—
—
cases:30.24%
controls:1.51%
cases:44.54%
controls:6.75%
cases:45.93%
controls:15.25%
82
529
417
4436
95
330
406
4645
98
63
403
4912
—
137
75
316
4893
159
331
198
4576
96
623
113
3463
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
FM1EE [2001303307]
6.5e-01
1.1e+00
3.9e+00
—
3.3e+00
1.4e+00
1.5e+00
cases:7.21%
controls:3.91%
cases:5.39%
controls:1.89%
cases:6.39%
controls:0.14%
—
—
cases:5.74%
controls:0.22%
cases:7.56%
controls:1.94%
cases:19.14%
controls:5.14%
36
194
463
4771
27
94
474
4881
32
7
469
4968
—
26
11
427
4957
27
95
330
4812
40
210
169
3876
ABO and Rh group [Type] in Blood
882-1 [3003694]
882-1 [3003694]
5.1e-01
6.3e-02
3.5e+00
1.0e+50
5.1e+00
2.3e+00
8.6e-01
cases:6.01%
controls:3.69%
cases:1.80%
controls:1.69%
cases:6.59%
controls:0.22%
cases:9.78%
controls:0.00%
cases:16.56%
controls:0.12%
cases:10.64%
controls:1.16%
cases:11.00%
controls:4.97%
30
183
469
4782
9
84
492
4891
33
11
468
4964
49
0
452
4975
75
6
378
4962
38
57
319
4850
23
203
186
3883
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
43730-1 [3043849]
—
2.3e+00
1.0e+50
1.0e+50
—
5.5e+00
3.9e+00
—
—
cases:1.20%
controls:0.12%
cases:2.59%
controls:0.00%
cases:4.99%
controls:0.00%
—
—
cases:20.73%
controls:0.10%
cases:12.44%
controls:0.29%
—
6
6
495
4969
13
0
488
4975
25
0
476
4975
—
74
5
283
4902
26
12
183
4074
valaciclovir; oral
J05AB11 [21603137]
J05AB11 [21603137]
5.7e-01
9.2e-01
—
—
4.2e+00
4.3e+00
3.1e+00
cases:2.40%
controls:1.37%
cases:1.60%
controls:0.64%
—
—
—
—
cases:6.18%
controls:0.10%
cases:32.77%
controls:0.67%
cases:29.19%
controls:1.86%
12
68
487
4897
8
32
493
4943
—
—
28
5
425
4963
117
33
240
4874
61
76
148
4010
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
1.6e-01
8.8e-02
3.4e+00
—
3.6e+00
2.9e+00
1.6e+00
cases:6.81%
controls:5.88%
cases:1.80%
controls:1.65%
cases:3.39%
controls:0.12%
—
—
cases:5.08%
controls:0.14%
cases:19.89%
controls:1.39%
cases:15.31%
controls:3.60%
34
292
465
4673
9
82
492
4893
17
6
484
4969
—
23
7
430
4961
71
68
286
4839
32
147
177
3939
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
4.6e-02
3.1e-01
2.4e+00
5.4e+00
2.7e+00
8.7e-01
8.3e-03
cases:36.67%
controls:35.61%
cases:32.93%
controls:26.47%
cases:34.33%
controls:4.48%
cases:23.35%
controls:0.14%
cases:39.51%
controls:4.13%
cases:48.46%
controls:28.33%
cases:47.37%
controls:47.16%
183
1768
316
3197
165
1317
336
3658
172
223
329
4752
117
7
384
4968
179
205
274
4763
173
1390
184
3517
99
1927
110
2159
Oncology Clinic/Center
261QX0200X [38004268]
261QX0200X [38004268]
3.4e+00
3.4e+00
—
1.0e+50
1.0e+50
—
4.4e+00
cases:11.22%
controls:0.40%
cases:3.99%
controls:0.14%
—
—
cases:97.80%
controls:0.00%
cases:4.86%
controls:0.00%
—
—
cases:14.83%
controls:0.22%
56
20
443
4945
20
7
481
4968
—
490
0
11
4975
22
0
431
4968
—
31
9
178
4077
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
5.0e-01
1.2e+00
2.3e+00
—
3.2e+00
2.4e+00
1.6e+00
cases:15.63%
controls:10.07%
cases:18.16%
controls:6.45%
cases:11.18%
controls:1.21%
—
—
cases:25.61%
controls:1.39%
cases:43.14%
controls:6.58%
cases:45.93%
controls:14.81%
78
500
421
4465
91
321
410
4654
56
60
445
4915
—
116
69
337
4899
154
323
203
4584
96
605
113
3481
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
4.7e-01
1.2e+00
2.4e+00
—
3.2e+00
2.4e+00
1.6e+00
cases:15.83%
controls:10.51%
cases:19.16%
controls:6.65%
cases:12.38%
controls:1.29%
—
—
cases:25.83%
controls:1.45%
cases:43.98%
controls:6.79%
cases:45.93%
controls:15.10%
79
522
420
4443
96
331
405
4644
62
64
439
4911
—
117
72
336
4896
157
333
200
4574
96
617
113
3469
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
4.8e-01
1.2e+00
2.3e+00
—
3.2e+00
2.4e+00
1.6e+00
cases:15.43%
controls:10.15%
cases:18.16%
controls:6.45%
cases:11.18%
controls:1.21%
—
—
cases:25.61%
controls:1.39%
cases:43.42%
controls:6.58%
cases:45.93%
controls:14.86%
77
504
422
4461
91
321
410
4654
56
60
445
4915
—
116
69
337
4899
155
323
202
4584
96
607
113
3479
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
EB1HA [2001301913]
2.6e-01
3.9e-02
3.9e+00
1.0e+50
3.8e+00
2.2e+00
1.2e+00
cases:9.42%
controls:7.43%
cases:1.80%
controls:1.73%
cases:6.39%
controls:0.14%
cases:2.20%
controls:0.00%
cases:6.18%
controls:0.14%
cases:10.64%
controls:1.37%
cases:17.22%
controls:5.85%
47
369
452
4596
9
86
492
4889
32
7
469
4968
11
0
490
4975
28
7
425
4961
38
67
319
4840
36
239
173
3847
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
3.5e-01
7.0e-01
2.9e+00
—
4.1e+00
2.3e+00
1.0e+00
cases:13.03%
controls:9.59%
cases:9.58%
controls:5.01%
cases:10.78%
controls:0.68%
—
—
cases:28.92%
controls:0.68%
cases:35.01%
controls:5.07%
cases:31.58%
controls:14.02%
65
476
434
4489
48
249
453
4726
54
34
447
4941
—
131
34
322
4934
125
249
232
4658
66
573
143
3513
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
3.3e-01
5.8e-01
3.2e+00
1.0e+50
4.5e+00
2.3e+00
9.8e-01
cases:6.61%
controls:4.83%
cases:4.19%
controls:2.39%
cases:8.78%
controls:0.40%
cases:9.78%
controls:0.00%
cases:17.66%
controls:0.24%
cases:19.61%
controls:2.30%
cases:15.79%
controls:6.56%
33
240
466
4725
21
119
480
4856
44
20
457
4955
49
0
452
4975
80
12
373
4956
70
113
287
4794
33
268
176
3818
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
4.5e-01
8.9e-01
—
1.0e+50
5.5e+00
3.5e+00
1.9e+00
cases:4.21%
controls:2.72%
cases:2.59%
controls:1.09%
—
—
cases:9.38%
controls:0.00%
cases:22.96%
controls:0.12%
cases:27.45%
controls:1.12%
cases:19.62%
controls:3.38%
21
135
478
4830
13
54
488
4921
—
47
0
454
4975
104
6
349
4962
98
55
259
4852
41
138
168
3948
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
4.5e-01
8.7e-01
3.2e+00
—
3.6e+00
1.9e+00
9.6e-01
cases:27.05%
controls:19.19%
cases:22.95%
controls:11.06%
cases:30.94%
controls:1.81%
—
—
cases:38.41%
controls:1.75%
cases:46.78%
controls:11.49%
cases:46.41%
controls:24.94%
135
953
364
4012
115
550
386
4425
155
90
346
4885
—
174
87
279
4881
167
564
190
4343
97
1019
112
3067
pH of Specimen
17433-4 [3019225]
17433-4 [3019225]
4.1e-01
1.0e+00
2.9e+00
1.0e+50
3.9e+00
1.9e+00
1.2e+00
cases:3.61%
controls:2.42%
cases:3.39%
controls:1.23%
cases:2.40%
controls:0.14%
cases:3.59%
controls:0.00%
cases:6.40%
controls:0.14%
cases:9.24%
controls:1.53%
cases:8.61%
controls:2.81%
18
120
481
4845
17
61
484
4914
12
7
489
4968
18
0
483
4975
29
7
424
4961
33
75
324
4832
18
115
191
3971
INR in Blood by Coagulation assay
34714-6 [3032080]
34714-6 [3032080]
4.4e-01
4.4e-01
1.6e+00
4.5e+00
2.1e+00
1.5e+00
5.8e-01
cases:17.23%
controls:11.82%
cases:10.58%
controls:7.08%
cases:12.97%
controls:2.87%
cases:13.17%
controls:0.16%
cases:18.32%
controls:2.70%
cases:26.61%
controls:7.50%
cases:22.49%
controls:13.93%
86
587
413
4378
53
352
448
4623
65
143
436
4832
66
8
435
4967
83
134
370
4834
95
368
262
4539
47
569
162
3517
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
1.4e-01
3.9e-01
2.2e+00
4.8e+00
2.4e+00
7.9e-01
1.5e-01
cases:26.25%
controls:23.67%
cases:26.35%
controls:19.46%
cases:29.34%
controls:4.28%
cases:24.95%
controls:0.26%
cases:32.23%
controls:4.27%
cases:37.25%
controls:21.26%
cases:37.80%
controls:34.24%
131
1175
368
3790
132
968
369
4007
147
213
354
4762
125
13
376
4962
146
212
307
4756
133
1043
224
3864
79
1399
130
2687
Anaemia, unspecified
D64.9 [45600610]
D64.9 [45600610]
1.6e+00
2.5e+00
—
1.0e+50
4.3e+00
2.2e+00
8.4e-01
cases:7.01%
controls:1.57%
cases:8.38%
controls:0.72%
—
—
cases:3.39%
controls:0.00%
cases:7.06%
controls:0.10%
cases:5.32%
controls:0.63%
cases:4.78%
controls:2.13%
35
78
464
4887
42
36
459
4939
—
17
0
484
4975
32
5
421
4963
19
31
338
4876
10
87
199
3999
Outpatient Hospital
22 [8756]
22 [8756]
3.0e-01
6.4e-01
3.0e+00
1.0e+50
3.5e+00
2.5e+00
9.9e-01
cases:32.87%
controls:26.71%
cases:12.57%
controls:7.06%
cases:14.77%
controls:0.86%
cases:5.79%
controls:0.00%
cases:21.19%
controls:0.85%
cases:45.66%
controls:6.44%
cases:36.36%
controls:17.50%
164
1326
335
3639
63
351
438
4624
74
43
427
4932
29
0
472
4975
96
42
357
4926
163
316
194
4591
76
715
133
3371
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
3.4e-01
7.3e-01
2.9e+00
—
3.8e+00
2.2e+00
9.8e-01
cases:14.23%
controls:10.51%
cases:11.58%
controls:5.95%
cases:15.57%
controls:1.05%
—
—
cases:31.57%
controls:0.99%
cases:39.78%
controls:7.07%
cases:35.41%
controls:17.01%
71
522
428
4443
58
296
443
4679
78
52
423
4923
—
143
49
310
4919
142
347
215
4560
74
695
135
3391
Inpatient Visit
IP [9201]
IP [9201]
6.1e-01
5.2e-01
3.0e+00
—
3.7e+00
2.4e+00
7.1e-01
cases:12.02%
controls:6.93%
cases:4.99%
controls:3.04%
cases:6.59%
controls:0.34%
—
—
cases:13.91%
controls:0.38%
cases:28.57%
controls:3.65%
cases:18.66%
controls:10.18%
60
344
439
4621
25
151
476
4824
33
17
468
4958
—
63
19
390
4949
102
179
255
4728
39
416
170
3670
Treatment plan or consultation
WZC00 [2001310885]
WZC00 [2001310885]
9.8e-01
9.1e-01
2.2e+00
—
3.2e+00
2.5e+00
1.6e+00
cases:8.62%
controls:3.42%
cases:2.59%
controls:1.07%
cases:1.40%
controls:0.16%
—
—
cases:4.42%
controls:0.18%
cases:15.13%
controls:1.49%
cases:18.66%
controls:4.55%
43
170
456
4795
13
53
488
4922
7
8
494
4967
—
20
9
433
4959
54
73
303
4834
39
186
170
3900
Body CT examination
JN4AD [2001310897]
JN4AD [2001310897]
2.2e+00
2.5e+00
—
1.0e+50
—
3.5e+00
2.1e+00
cases:2.20%
controls:0.24%
cases:2.00%
controls:0.16%
—
—
cases:2.79%
controls:0.00%
—
—
cases:7.84%
controls:0.24%
cases:5.74%
controls:0.76%
11
12
488
4953
10
8
491
4967
—
14
0
487
4975
—
28
12
329
4895
12
31
197
4055
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
2.3e-01
5.7e-01
2.9e+00
—
3.8e+00
2.2e+00
9.8e-01
cases:11.82%
controls:9.65%
cases:8.98%
controls:5.29%
cases:13.97%
controls:0.92%
—
—
cases:27.59%
controls:0.87%
cases:35.85%
controls:6.09%
cases:30.62%
controls:14.22%
59
479
440
4486
45
263
456
4712
70
46
431
4929
—
125
43
328
4925
128
299
229
4608
64
581
145
3505
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
1.2e-02
2.1e-01
2.3e+00
4.8e+00
2.5e+00
7.5e-01
3.7e-02
cases:37.07%
controls:36.80%
cases:33.53%
controls:29.13%
cases:35.53%
controls:5.31%
cases:29.14%
controls:0.34%
cases:41.72%
controls:5.48%
cases:49.30%
controls:31.55%
cases:48.80%
controls:47.87%
185
1827
314
3138
168
1449
333
3526
178
264
323
4711
146
17
355
4958
189
272
264
4696
176
1548
181
3359
102
1956
107
2130
Urgent procedure
ZXD05 [2001311386]
ZXD05 [2001311386]
8.5e-02
5.5e-01
3.8e+00
—
3.6e+00
2.9e+00
6.6e-01
cases:4.61%
controls:4.25%
cases:1.80%
controls:1.05%
cases:4.39%
controls:0.10%
—
—
cases:4.86%
controls:0.14%
cases:15.41%
controls:1.00%
cases:6.22%
controls:3.33%
23
211
476
4754
9
52
492
4923
22
5
479
4970
—
22
7
431
4961
55
49
302
4858
13
136
196
3950
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
1.1e-02
2.3e-01
2.3e+00
4.7e+00
2.5e+00
7.6e-01
4.3e-02
cases:36.87%
controls:36.62%
cases:33.53%
controls:28.70%
cases:35.33%
controls:5.19%
cases:28.94%
controls:0.36%
cases:41.50%
controls:5.41%
cases:49.02%
controls:31.12%
cases:48.80%
controls:47.72%
184
1818
315
3147
168
1428
333
3547
177
258
324
4717
145
18
356
4957
188
269
265
4699
175
1527
182
3380
102
1950
107
2136
Outpatient Visit
OP [9202]
OP [9202]
2.4e-01
3.5e-01
1.5e+00
3.0e+00
1.7e+00
2.2e+00
1.5e+00
cases:76.75%
controls:72.25%
cases:60.28%
controls:51.74%
cases:34.73%
controls:10.65%
cases:9.58%
controls:0.54%
cases:39.29%
controls:10.63%
cases:91.32%
controls:52.66%
cases:94.26%
controls:78.68%
383
3587
116
1378
302
2574
199
2401
174
530
327
4445
48
27
453
4948
178
528
275
4440
326
2584
31
2323
197
3215
12
871
Emergency Room Visit
ER [9203]
ER [9203]
2.3e-01
7.2e-01
3.3e+00
—
3.0e+00
2.1e+00
1.1e+00
cases:40.88%
controls:35.39%
cases:22.36%
controls:12.34%
cases:30.34%
controls:1.59%
—
—
cases:21.63%
controls:1.37%
cases:52.38%
controls:11.78%
cases:58.37%
controls:31.38%
204
1757
295
3208
112
614
389
4361
152
79
349
4896
—
98
68
355
4900
187
578
170
4329
122
1282
87
2804
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
5.4e-02
2.5e-01
2.3e+00
4.9e+00
2.4e+00
6.4e-01
-6.8e-02
cases:41.28%
controls:39.98%
cases:39.12%
controls:33.27%
cases:42.32%
controls:7.02%
cases:35.93%
controls:0.40%
cases:44.37%
controls:6.98%
cases:50.98%
controls:35.52%
cases:50.24%
controls:51.93%
206
1985
293
2980
196
1655
305
3320
212
349
289
4626
180
20
321
4955
201
347
252
4621
182
1743
175
3164
105
2122
104
1964
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
5.6e-02
2.5e-01
2.3e+00
4.9e+00
2.4e+00
6.3e-01
-5.2e-02
cases:41.28%
controls:39.94%
cases:39.12%
controls:33.27%
cases:42.32%
controls:7.02%
cases:35.93%
controls:0.40%
cases:44.37%
controls:7.00%
cases:50.98%
controls:35.58%
cases:50.72%
controls:52.01%
206
1983
293
2982
196
1655
305
3320
212
349
289
4626
180
20
321
4955
201
348
252
4620
182
1746
175
3161
106
2125
103
1961
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
5.2e-02
2.5e-01
2.3e+00
4.9e+00
2.4e+00
6.3e-01
-7.0e-02
cases:41.28%
controls:40.02%
cases:39.12%
controls:33.31%
cases:42.32%
controls:7.02%
cases:35.93%
controls:0.40%
cases:44.37%
controls:7.00%
cases:50.98%
controls:35.60%
cases:50.24%
controls:51.98%
206
1987
293
2978
196
1657
305
3318
212
349
289
4626
180
20
321
4955
201
348
252
4620
182
1747
175
3160
105
2124
104
1962
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
5.3e-02
2.5e-01
2.3e+00
4.9e+00
2.4e+00
6.3e-01
-5.2e-02
cases:41.28%
controls:40.00%
cases:39.12%
controls:33.33%
cases:42.32%
controls:7.02%
cases:35.93%
controls:0.40%
cases:44.37%
controls:7.00%
cases:50.98%
controls:35.66%
cases:50.72%
controls:52.01%
206
1986
293
2979
196
1658
305
3317
212
349
289
4626
180
20
321
4955
201
348
252
4620
182
1750
175
3157
106
2125
103
1961
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
5.2e-02
2.5e-01
2.3e+00
4.9e+00
2.4e+00
6.3e-01
-5.1e-02
cases:41.28%
controls:40.02%
cases:39.12%
controls:33.31%
cases:42.32%
controls:7.02%
cases:35.93%
controls:0.40%
cases:44.37%
controls:7.02%
cases:50.98%
controls:35.60%
cases:50.72%
controls:51.98%
206
1987
293
2978
196
1657
305
3318
212
349
289
4626
180
20
321
4955
201
349
252
4619
182
1747
175
3160
106
2124
103
1962
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
6.2e-02
2.4e-01
2.3e+00
4.9e+00
2.4e+00
6.3e-01
-5.1e-02
cases:41.48%
controls:39.98%
cases:38.92%
controls:33.35%
cases:42.32%
controls:7.02%
cases:35.93%
controls:0.40%
cases:44.37%
controls:7.00%
cases:50.98%
controls:35.68%
cases:50.72%
controls:51.98%
207
1985
292
2980
195
1659
306
3316
212
349
289
4626
180
20
321
4955
201
348
252
4620
182
1751
175
3156
106
2124
103
1962
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
5.9e-02
2.5e-01
2.3e+00
4.9e+00
2.4e+00
6.3e-01
-5.3e-02
cases:41.48%
controls:40.06%
cases:39.12%
controls:33.35%
cases:42.32%
controls:7.06%
cases:35.93%
controls:0.40%
cases:44.37%
controls:7.00%
cases:50.98%
controls:35.70%
cases:50.72%
controls:52.03%
207
1989
292
2976
196
1659
305
3316
212
351
289
4624
180
20
321
4955
201
348
252
4620
182
1752
175
3155
106
2126
103
1960
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
3.0e-01
3.5e-01
2.9e+00
—
2.5e+00
2.6e+00
2.1e+00
cases:5.01%
controls:3.77%
cases:1.60%
controls:1.13%
cases:3.19%
controls:0.18%
—
—
cases:2.65%
controls:0.22%
cases:12.04%
controls:1.02%
cases:18.18%
controls:2.59%
25
187
474
4778
8
56
493
4919
16
9
485
4966
—
12
11
441
4957
43
50
314
4857
38
106
171
3980
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
J01EE01 [21602961]
1.5e+00
1.6e+00
—
—
1.0e+50
5.9e+00
4.2e+00
cases:1.40%
controls:0.32%
cases:1.00%
controls:0.20%
—
—
—
—
cases:4.64%
controls:0.00%
cases:31.09%
controls:0.12%
cases:27.75%
controls:0.59%
7
16
492
4949
5
10
496
4965
—
—
21
0
432
4968
111
6
246
4901
58
24
151
4062
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
7.7e-02
6.6e-01
3.1e+00
—
3.7e+00
2.1e+00
1.0e+00
cases:6.21%
controls:5.78%
cases:5.59%
controls:2.97%
cases:8.98%
controls:0.42%
—
—
cases:18.76%
controls:0.58%
cases:23.25%
controls:3.55%
cases:22.97%
controls:9.54%
31
287
468
4678
28
148
473
4827
45
21
456
4954
—
85
29
368
4939
83
174
274
4733
48
390
161
3696
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
1.7e-01
3.7e-01
2.2e+00
4.5e+00
2.1e+00
7.9e-01
8.2e-02
cases:28.86%
controls:25.54%
cases:28.14%
controls:21.37%
cases:27.35%
controls:4.12%
cases:19.16%
controls:0.26%
cases:26.49%
controls:4.25%
cases:40.34%
controls:23.46%
cases:41.15%
controls:39.18%
144
1268
355
3697
141
1063
360
3912
137
205
364
4770
96
13
405
4962
120
211
333
4757
144
1151
213
3756
86
1601
123
2485
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
-5.6e-03
2.3e-01
2.2e+00
4.7e+00
2.4e+00
6.8e-01
-2.5e-02
cases:38.28%
controls:38.41%
cases:36.93%
controls:31.66%
cases:38.52%
controls:6.45%
cases:30.94%
controls:0.42%
cases:42.83%
controls:6.58%
cases:50.42%
controls:34.05%
cases:49.28%
controls:49.90%
191
1907
308
3058
185
1575
316
3400
193
321
308
4654
155
21
346
4954
194
327
259
4641
180
1671
177
3236
103
2039
106
2047
Medical Oncology
90 [38004507]
90 [38004507]
4.8e+00
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
5.1e+00
cases:10.62%
controls:0.10%
—
—
cases:4.39%
controls:0.00%
cases:1.00%
controls:0.00%
cases:4.86%
controls:0.00%
cases:14.85%
controls:0.00%
cases:16.75%
controls:0.12%
53
5
446
4960
—
22
0
479
4975
5
0
496
4975
22
0
431
4968
53
0
304
4907
35
5
174
4081
Inpatient Hospital
21 [8717]
21 [8717]
2.7e-01
7.4e-01
3.0e+00
1.0e+50
3.2e+00
2.2e+00
6.7e-01
cases:40.28%
controls:34.08%
cases:20.36%
controls:10.87%
cases:27.35%
controls:1.83%
cases:9.38%
controls:0.00%
cases:33.77%
controls:2.03%
cases:52.10%
controls:10.78%
cases:40.67%
controls:25.89%
201
1692
298
3273
102
541
399
4434
137
91
364
4884
47
0
454
4975
153
101
300
4867
186
529
171
4378
85
1058
124
3028
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
16128-1 [3017143]
9.2e-01
1.1e+00
—
—
4.8e+00
3.1e+00
1.9e+00
cases:3.21%
controls:1.31%
cases:2.20%
controls:0.76%
—
—
—
—
cases:12.58%
controls:0.12%
cases:12.32%
controls:0.65%
cases:8.13%
controls:1.25%
16
65
483
4900
11
38
490
4937
—
—
57
6
396
4962
44
32
313
4875
17
51
192
4035
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
28541-1 [3002179]
1.5e+00
2.3e+00
—
1.0e+50
—
3.9e+00
2.1e+00
cases:3.01%
controls:0.68%
cases:5.59%
controls:0.58%
—
—
cases:12.18%
controls:0.00%
—
—
cases:22.97%
controls:0.61%
cases:17.70%
controls:2.64%
15
34
484
4931
28
29
473
4946
—
61
0
440
4975
—
82
30
275
4877
37
108
172
3978
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
22664-7 [3020779]
-2.8e-01
5.5e-02
1.9e+00
—
3.3e+00
2.9e+00
1.7e+00
cases:1.20%
controls:1.59%
cases:1.00%
controls:0.94%
cases:1.40%
controls:0.22%
—
—
cases:7.95%
controls:0.32%
cases:13.73%
controls:0.84%
cases:11.48%
controls:2.40%
6
79
493
4886
5
47
496
4928
7
11
494
4964
—
36
16
417
4952
49
41
308
4866
24
98
185
3988
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1798-8 [3016771]
2.4e-01
7.8e-01
2.9e+00
—
3.5e+00
1.7e+00
8.4e-01
cases:7.62%
controls:6.10%
cases:4.79%
controls:2.25%
cases:4.99%
controls:0.30%
—
—
cases:3.97%
controls:0.12%
cases:14.29%
controls:2.91%
cases:15.79%
controls:7.49%
38
303
461
4662
24
112
477
4863
25
15
476
4960
—
18
6
435
4962
51
143
306
4764
33
306
176
3780
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
14732-2 [3021960]
2.2e-01
9.3e-01
3.7e+00
1.0e+50
3.9e+00
1.2e+00
3.3e-01
cases:3.41%
controls:2.76%
cases:5.79%
controls:2.37%
cases:10.18%
controls:0.28%
cases:5.99%
controls:0.00%
cases:7.28%
controls:0.16%
cases:8.96%
controls:2.95%
cases:14.83%
controls:11.14%
17
137
482
4828
29
118
472
4857
51
14
450
4961
30
0
471
4975
33
8
420
4960
32
145
325
4762
31
455
178
3631
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
14731-4 [3019309]
4.4e-01
1.4e+00
3.6e+00
—
2.3e+00
1.4e+00
9.6e-01
cases:9.42%
controls:6.26%
cases:5.99%
controls:1.61%
cases:4.39%
controls:0.12%
—
—
cases:1.55%
controls:0.16%
cases:5.32%
controls:1.32%
cases:8.13%
controls:3.28%
47
311
452
4654
30
80
471
4895
22
6
479
4969
—
7
8
446
4960
19
65
338
4842
17
134
192
3952
Pneumonia, unspecified
J18.9 [45601123]
J18.9 [45601123]
6.2e-01
1.2e+00
3.5e+00
1.0e+50
2.1e+00
1.9e+00
9.6e-01
cases:6.01%
controls:3.32%
cases:4.99%
controls:1.55%
cases:4.39%
controls:0.14%
cases:1.20%
controls:0.00%
cases:2.65%
controls:0.34%
cases:11.48%
controls:1.85%
cases:16.75%
controls:7.12%
30
165
469
4800
25
77
476
4898
22
7
479
4968
6
0
495
4975
12
17
441
4951
41
91
316
4816
35
291
174
3795
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
5.4e-01
9.6e-01
3.1e+00
1.0e+50
2.8e+00
1.9e+00
8.5e-01
cases:8.22%
controls:4.97%
cases:5.99%
controls:2.39%
cases:7.19%
controls:0.34%
cases:4.99%
controls:0.00%
cases:7.06%
controls:0.46%
cases:13.73%
controls:2.36%
cases:14.35%
controls:6.71%
41
247
458
4718
30
119
471
4856
36
17
465
4958
25
0
476
4975
32
23
421
4945
49
116
308
4791
30
274
179
3812
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
2.3e-02
2.1e-01
2.1e+00
4.5e+00
2.3e+00
6.6e-01
5.5e-02
cases:34.87%
controls:34.34%
cases:26.55%
controls:22.67%
cases:26.75%
controls:4.38%
cases:18.36%
controls:0.24%
cases:28.92%
controls:4.03%
cases:36.41%
controls:22.89%
cases:41.63%
controls:40.31%
174
1705
325
3260
133
1128
368
3847
134
218
367
4757
92
12
409
4963
131
200
322
4768
130
1123
227
3784
87
1647
122
2439
nystatin; oral
A07AA02 [21600604]
A07AA02 [21600604]
8.4e-01
-1.0e+50
—
—
2.6e+00
4.1e+00
2.7e+00
cases:1.80%
controls:0.79%
cases:0.00%
controls:0.16%
—
—
—
—
cases:1.32%
controls:0.10%
cases:12.32%
controls:0.22%
cases:11.48%
controls:0.83%
9
39
490
4926
0
8
501
4967
—
—
6
5
447
4963
44
11
313
4896
24
34
185
4052
Complement+Immunoglobulin [Units/volume] in Red Blood Cells
4533-6 [3024403]
4533-6 [3024403]
1.3e+00
2.7e+00
—
1.0e+50
—
4.2e+00
2.5e+00
cases:1.40%
controls:0.40%
cases:2.99%
controls:0.20%
—
—
cases:5.59%
controls:0.00%
—
—
cases:9.52%
controls:0.16%
cases:5.26%
controls:0.44%
7
20
492
4945
15
10
486
4965
—
28
0
473
4975
—
34
8
323
4899
11
18
198
4068
Physiotherapist
Z3226 [2001311560]
Z3226 [2001311560]
-7.9e-02
—
2.7e+00
—
2.8e+00
2.4e+00
1.5e+00
cases:1.60%
controls:1.73%
—
—
cases:1.80%
controls:0.12%
—
—
cases:2.21%
controls:0.14%
cases:7.00%
controls:0.67%
cases:6.22%
controls:1.44%
8
86
491
4879
—
9
6
492
4969
—
10
7
443
4961
25
33
332
4874
13
59
196
4027
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
2.0e-01
6.5e-01
3.8e+00
1.0e+50
2.9e+00
2.0e+00
6.2e-01
cases:5.41%
controls:4.49%
cases:5.79%
controls:3.12%
cases:14.17%
controls:0.36%
cases:3.99%
controls:0.00%
cases:9.49%
controls:0.56%
cases:24.37%
controls:4.24%
cases:20.10%
controls:11.94%
27
223
472
4742
29
155
472
4820
71
18
430
4957
20
0
481
4975
43
28
410
4940
87
208
270
4699
42
488
167
3598
ursodeoxycholic acid; oral
A05AA02 [21600513]
A05AA02 [21600513]
—
—
—
—
—
5.0e+00
4.3e+00
—
—
—
—
—
—
—
—
—
—
cases:17.93%
controls:0.14%
cases:12.44%
controls:0.20%
—
—
—
—
—
64
7
293
4900
26
8
183
4078
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
-1.6e-02
1.2e-01
2.0e+00
4.7e+00
2.0e+00
4.7e-01
1.5e-02
cases:29.26%
controls:29.59%
cases:25.15%
controls:23.04%
cases:26.35%
controls:4.78%
cases:21.36%
controls:0.24%
cases:27.59%
controls:4.73%
cases:34.17%
controls:24.52%
cases:37.32%
controls:36.98%
146
1469
353
3496
126
1146
375
3829
132
238
369
4737
107
12
394
4963
125
235
328
4733
122
1203
235
3704
78
1511
131
2575
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
1.5e-01
3.0e-01
2.8e+00
—
3.4e+00
2.0e+00
9.5e-01
cases:15.43%
controls:13.62%
cases:8.98%
controls:6.83%
cases:12.18%
controls:0.82%
—
—
cases:20.53%
controls:0.83%
cases:34.73%
controls:7.03%
cases:35.41%
controls:17.52%
77
676
422
4289
45
340
456
4635
61
41
440
4934
—
93
41
360
4927
124
345
233
4562
74
716
135
3370
Epstein Barr virus Ab [Presence] in Serum
49178-7 [3048929]
49178-7 [3048929]
—
2.0e+00
1.0e+50
1.0e+50
—
4.4e+00
2.7e+00
—
—
cases:1.20%
controls:0.16%
cases:4.39%
controls:0.00%
cases:11.98%
controls:0.00%
—
—
cases:10.36%
controls:0.14%
cases:5.74%
controls:0.42%
—
6
8
495
4967
22
0
479
4975
60
0
441
4975
—
37
7
320
4900
12
17
197
4069
Blasts/Leukocytes in Blood
26446-5 [3025159]
26446-5 [3025159]
1.3e+00
2.0e+00
—
1.0e+50
—
3.7e+00
2.0e+00
cases:2.61%
controls:0.73%
cases:4.59%
controls:0.62%
—
—
cases:11.98%
controls:0.00%
—
—
cases:21.85%
controls:0.67%
cases:17.22%
controls:2.67%
13
36
486
4929
23
31
478
4944
—
60
0
441
4975
—
78
33
279
4874
36
109
173
3977
Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
38917-1 [3042194]
38917-1 [3042194]
1.3e+00
—
—
—
1.0e+50
5.3e+00
3.8e+00
cases:1.40%
controls:0.38%
—
—
—
—
—
—
cases:8.39%
controls:0.00%
cases:19.89%
controls:0.12%
cases:15.31%
controls:0.42%
7
19
492
4946
—
—
—
38
0
415
4968
71
6
286
4901
32
17
177
4069
Human bocavirus DNA [Presence] in Specimen by NAA with probe detection
62424-7 [40765161]
62424-7 [40765161]
9.7e-01
—
—
1.0e+50
1.0e+50
5.1e+00
3.9e+00
cases:1.00%
controls:0.38%
—
—
—
—
cases:1.60%
controls:0.00%
cases:8.83%
controls:0.00%
cases:16.81%
controls:0.12%
cases:11.96%
controls:0.27%
5
19
494
4946
—
—
8
0
493
4975
40
0
413
4968
60
6
297
4901
25
11
184
4075
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
J01CR02 [21602863]
3.4e-01
4.4e-01
2.5e+00
—
2.6e+00
2.7e+00
1.2e+00
cases:8.82%
controls:6.45%
cases:2.59%
controls:1.69%
cases:1.40%
controls:0.12%
—
—
cases:2.43%
controls:0.18%
cases:18.21%
controls:1.53%
cases:21.53%
controls:7.42%
44
320
455
4645
13
84
488
4891
7
6
494
4969
—
11
9
442
4959
65
75
292
4832
45
303
164
3783
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
2458-8 [3007164]
2.7e-01
1.1e+00
—
1.0e+50
4.8e+00
2.0e+00
1.1e+00
cases:4.01%
controls:3.08%
cases:3.19%
controls:1.13%
—
—
cases:8.38%
controls:0.00%
cases:10.82%
controls:0.10%
cases:7.28%
controls:1.10%
cases:10.53%
controls:3.65%
20
153
479
4812
16
56
485
4919
—
42
0
459
4975
49
5
404
4963
26
54
331
4853
22
149
187
3937
moxifloxacin; oral, parenteral
J01MA14 [21603021]
J01MA14 [21603021]
1.1e+00
2.0e+00
—
—
—
3.8e+00
2.1e+00
cases:2.61%
controls:0.85%
cases:1.40%
controls:0.20%
—
—
—
—
—
—
cases:8.96%
controls:0.22%
cases:7.18%
controls:0.98%
13
42
486
4923
7
10
494
4965
—
—
—
32
11
325
4896
15
40
194
4046
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
1.0e-01
6.3e-01
3.1e+00
1.0e+50
3.3e+00
2.5e+00
8.0e-01
cases:4.61%
controls:4.19%
cases:2.20%
controls:1.19%
cases:4.59%
controls:0.22%
cases:1.40%
controls:0.00%
cases:4.86%
controls:0.18%
cases:15.97%
controls:1.55%
cases:9.57%
controls:4.55%
23
208
476
4757
11
59
490
4916
23
11
478
4964
7
0
494
4975
22
9
431
4959
57
76
300
4831
20
186
189
3900
oxycodone; oral, parenteral
N02AA05 [21604260]
N02AA05 [21604260]
4.8e-01
8.6e-01
2.0e+00
—
2.8e+00
2.8e+00
1.3e+00
cases:2.20%
controls:1.37%
cases:1.60%
controls:0.68%
cases:1.40%
controls:0.20%
—
—
cases:2.87%
controls:0.18%
cases:15.13%
controls:1.08%
cases:10.05%
controls:2.84%
11
68
488
4897
8
34
493
4941
7
10
494
4965
—
13
9
440
4959
54
53
303
4854
21
116
188
3970
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2276-4 [3001122]
3.2e-01
9.9e-01
3.1e+00
—
2.1e+00
1.6e+00
1.1e+00
cases:9.62%
controls:7.15%
cases:10.98%
controls:4.36%
cases:13.57%
controls:0.68%
—
—
cases:3.97%
controls:0.52%
cases:20.45%
controls:4.93%
cases:33.01%
controls:14.24%
48
355
451
4610
55
217
446
4758
68
34
433
4941
—
18
26
435
4942
73
242
284
4665
69
582
140
3504
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
72493-0 [43055120]
—
1.9e+00
—
1.0e+50
—
4.8e+00
4.0e+00
—
—
cases:1.20%
controls:0.18%
—
—
cases:5.39%
controls:0.00%
—
—
cases:22.13%
controls:0.22%
cases:18.18%
controls:0.39%
—
6
9
495
4966
—
27
0
474
4975
—
79
11
278
4896
38
16
171
4070
Cathetrisation of vein
TPH04 [2001309597]
TPH04 [2001309597]
3.9e-01
5.9e-01
2.5e+00
—
2.8e+00
2.3e+00
1.2e+00
cases:4.01%
controls:2.74%
cases:2.40%
controls:1.35%
cases:2.99%
controls:0.26%
—
—
cases:3.53%
controls:0.22%
cases:10.08%
controls:1.08%
cases:10.05%
controls:3.18%
20
136
479
4829
12
67
489
4908
15
13
486
4962
—
16
11
437
4957
36
53
321
4854
21
130
188
3956
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
40982-1 [3038288]
7.0e-02
6.7e-01
—
1.0e+50
4.1e+00
3.1e+00
1.6e+00
cases:1.40%
controls:1.31%
cases:1.60%
controls:0.82%
—
—
cases:1.20%
controls:0.00%
cases:8.17%
controls:0.14%
cases:19.89%
controls:1.14%
cases:15.31%
controls:3.55%
7
65
492
4900
8
41
493
4934
—
6
0
495
4975
37
7
416
4961
71
56
286
4851
32
145
177
3941
Bone marrow biopsy
XW000 [2001310618]
XW000 [2001310618]
2.5e+00
—
1.0e+50
1.0e+50
1.0e+50
—
6.2e+00
cases:4.21%
controls:0.34%
—
—
cases:16.17%
controls:0.00%
cases:10.38%
controls:0.00%
cases:11.70%
controls:0.00%
—
—
cases:49.76%
controls:0.20%
21
17
478
4948
—
81
0
420
4975
52
0
449
4975
53
0
400
4968
—
104
8
105
4078
Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
40976-3 [3040853]
40976-3 [3040853]
1.3e+00
—
—
1.0e+50
1.0e+50
5.1e+00
3.6e+00
cases:1.40%
controls:0.38%
—
—
—
—
cases:1.60%
controls:0.00%
cases:9.71%
controls:0.00%
cases:21.57%
controls:0.16%
cases:15.79%
controls:0.49%
7
19
492
4946
—
—
8
0
493
4975
44
0
409
4968
77
8
280
4899
33
20
176
4066
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
47598-8 [3048816]
-4.8e-02
4.6e-01
3.0e+00
1.0e+50
3.9e+00
1.9e+00
6.9e-01
cases:1.40%
controls:1.47%
cases:1.40%
controls:0.88%
cases:2.00%
controls:0.10%
cases:2.40%
controls:0.00%
cases:4.64%
controls:0.10%
cases:4.76%
controls:0.77%
cases:4.31%
controls:2.20%
7
73
492
4892
7
44
494
4931
10
5
491
4970
12
0
489
4975
21
5
432
4963
17
38
340
4869
9
90
200
3996
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1920-8 [3013721]
4.2e-01
5.8e-01
2.9e+00
1.0e+50
3.3e+00
1.6e+00
8.6e-01
cases:9.42%
controls:6.38%
cases:4.79%
controls:2.73%
cases:6.19%
controls:0.36%
cases:6.19%
controls:0.00%
cases:11.48%
controls:0.48%
cases:14.29%
controls:3.16%
cases:17.22%
controls:8.13%
47
317
452
4648
24
136
477
4839
31
18
470
4957
31
0
470
4975
52
24
401
4944
51
155
306
4752
36
332
173
3754
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
2075-0 [3014576]
4.7e-01
2.7e-01
2.0e+00
—
3.4e+00
2.1e+00
1.1e+00
cases:2.61%
controls:1.65%
cases:1.40%
controls:1.07%
cases:2.00%
controls:0.28%
—
—
cases:3.53%
controls:0.12%
cases:9.80%
controls:1.28%
cases:11.00%
controls:4.04%
13
82
486
4883
7
53
494
4922
10
14
491
4961
—
16
6
437
4962
35
63
322
4844
23
165
186
3921
fluconazole; oral, parenteral
J02AC01 [21603080]
J02AC01 [21603080]
3.7e-01
3.9e-01
-1.0e+50
—
3.3e+00
3.3e+00
1.9e+00
cases:5.81%
controls:4.07%
cases:1.60%
controls:1.09%
cases:0.00%
controls:0.18%
—
—
cases:2.65%
controls:0.10%
cases:20.73%
controls:0.92%
cases:18.18%
controls:3.30%
29
202
470
4763
8
54
493
4921
0
9
501
4966
—
12
5
441
4963
74
45
283
4862
38
135
171
3951
Fungus identified in Specimen by Culture
580-1 [3000494]
580-1 [3000494]
2.2e-01
—
—
—
4.0e+00
3.1e+00
1.5e+00
cases:3.01%
controls:2.44%
—
—
—
—
—
—
cases:5.96%
controls:0.12%
cases:14.01%
controls:0.75%
cases:9.09%
controls:2.23%
15
121
484
4844
—
—
—
27
6
426
4962
50
37
307
4870
19
91
190
3995
aciclovir; oral, parenteral
J05AB01 [21603131]
J05AB01 [21603131]
3.3e-01
8.0e-01
-1.0e+50
—
3.0e+00
3.2e+00
2.3e+00
cases:3.21%
controls:2.32%
cases:1.60%
controls:0.72%
cases:0.00%
controls:0.12%
—
—
cases:1.99%
controls:0.10%
cases:14.57%
controls:0.69%
cases:18.18%
controls:2.25%
16
115
483
4850
8
36
493
4939
0
6
501
4969
—
9
5
444
4963
52
34
305
4873
38
92
171
3994
Standard cardiac ultrasound examination
FM1AE [2001303278]
FM1AE [2001303278]
-3.3e-01
-1.0e-01
3.2e+00
—
2.4e+00
1.8e+00
9.3e-01
cases:2.40%
controls:3.32%
cases:1.40%
controls:1.55%
cases:2.99%
controls:0.12%
—
—
cases:1.99%
controls:0.18%
cases:7.56%
controls:1.28%
cases:8.61%
controls:3.60%
12
165
487
4800
7
77
494
4898
15
6
486
4969
—
9
9
444
4959
27
63
330
4844
18
147
191
3939
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
7.7e-02
5.5e-01
2.7e+00
—
2.7e+00
1.6e+00
8.3e-01
cases:8.82%
controls:8.22%
cases:11.38%
controls:6.89%
cases:18.16%
controls:1.49%
—
—
cases:20.31%
controls:1.69%
cases:27.73%
controls:7.34%
cases:28.23%
controls:14.61%
44
408
455
4557
57
343
444
4632
91
74
410
4901
—
92
84
361
4884
99
360
258
4547
59
597
150
3489
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
-3.1e-03
1.5e-01
1.7e+00
4.5e+00
1.7e+00
3.7e-01
-1.5e-01
cases:43.29%
controls:43.36%
cases:43.11%
controls:39.56%
cases:44.51%
controls:12.88%
cases:38.92%
controls:0.72%
cases:45.03%
controls:12.50%
cases:51.54%
controls:42.45%
cases:51.20%
controls:54.89%
216
2153
283
2812
216
1968
285
3007
223
641
278
4334
195
36
306
4939
204
621
249
4347
184
2083
173
2824
107
2243
102
1843
ciclosporin; oral, parenteral
L04AD01 [21603924]
L04AD01 [21603924]
—
—
-1.0e+50
—
-1.0e+50
4.0e+00
4.2e+00
—
—
—
—
cases:0.00%
controls:0.10%
—
—
cases:0.00%
controls:0.18%
cases:13.73%
controls:0.29%
cases:17.70%
controls:0.32%
—
—
0
5
501
4970
—
0
9
453
4959
49
14
308
4893
37
13
172
4073
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
72160-5 [43054903]
2.4e-01
8.8e-01
3.6e+00
—
2.9e+00
8.7e-01
3.7e-01
cases:12.22%
controls:9.87%
cases:10.58%
controls:4.66%
cases:15.77%
controls:0.52%
—
—
cases:6.40%
controls:0.38%
cases:12.04%
controls:5.42%
cases:22.49%
controls:16.67%
61
490
438
4475
53
232
448
4743
79
26
422
4949
—
29
19
424
4949
43
266
314
4641
47
681
162
3405
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
1.2e-01
1.8e-01
2.6e+00
1.0e+50
2.7e+00
2.1e+00
8.0e-01
cases:8.22%
controls:7.35%
cases:4.59%
controls:3.86%
cases:7.39%
controls:0.56%
cases:2.40%
controls:0.00%
cases:7.73%
controls:0.58%
cases:23.81%
controls:3.81%
cases:21.05%
controls:10.74%
41
365
458
4600
23
192
478
4783
37
28
464
4947
12
0
489
4975
35
29
418
4939
85
187
272
4720
44
439
165
3647
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
30248-9 [3015399]
4.5e-01
1.3e+00
3.6e+00
—
1.8e+00
1.4e+00
4.8e-01
cases:7.82%
controls:5.14%
cases:8.58%
controls:2.53%
cases:10.18%
controls:0.30%
—
—
cases:1.77%
controls:0.28%
cases:9.80%
controls:2.69%
cases:12.92%
controls:8.44%
39
255
460
4710
43
126
458
4849
51
15
450
4960
—
8
14
445
4954
35
132
322
4775
27
345
182
3741
Bacterial infection, unspecified
A49.9 [45590816]
A49.9 [45590816]
9.8e-01
2.1e+00
—
—
—
3.7e+00
2.2e+00
cases:3.01%
controls:1.15%
cases:2.99%
controls:0.36%
—
—
—
—
—
—
cases:20.17%
controls:0.59%
cases:14.83%
controls:1.88%
15
57
484
4908
15
18
486
4957
—
—
—
72
29
285
4878
31
77
178
4009
Extensive body CT
JN4BD [2001310899]
JN4BD [2001310899]
2.3e+00
3.2e+00
—
1.0e+50
—
—
2.5e+00
cases:4.81%
controls:0.48%
cases:2.79%
controls:0.12%
—
—
cases:1.20%
controls:0.00%
—
—
—
—
cases:3.83%
controls:0.32%
24
24
475
4941
14
6
487
4969
—
6
0
495
4975
—
—
8
13
201
4073
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
16933-4 [3021879]
3.6e-01
2.0e+00
—
1.0e+50
—
3.8e+00
2.2e+00
cases:1.40%
controls:0.99%
cases:2.20%
controls:0.30%
—
—
cases:10.98%
controls:0.00%
—
—
cases:12.61%
controls:0.31%
cases:5.74%
controls:0.69%
7
49
492
4916
11
15
490
4960
—
55
0
446
4975
—
45
15
312
4892
12
28
197
4058
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
J01MA02 [21603009]
3.7e-01
6.5e-01
2.5e+00
—
2.3e+00
2.1e+00
1.0e+00
cases:8.22%
controls:5.84%
cases:3.19%
controls:1.69%
cases:2.00%
controls:0.16%
—
—
cases:2.21%
controls:0.22%
cases:15.13%
controls:2.04%
cases:14.83%
controls:5.97%
41
290
458
4675
16
84
485
4891
10
8
491
4967
—
10
11
443
4957
54
100
303
4807
31
244
178
3842
darbepoetin alfa; parenteral
B03XA02 [21601134]
B03XA02 [21601134]
—
2.0e+00
—
—
—
2.9e+00
3.1e+00
—
—
cases:1.40%
controls:0.20%
—
—
—
—
—
—
cases:3.64%
controls:0.20%
cases:5.26%
controls:0.24%
—
7
10
494
4965
—
—
—
13
10
344
4897
11
10
198
4076
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
J01MA12 [21603019]
1.0e+00
1.5e+00
—
—
—
3.6e+00
1.9e+00
cases:5.81%
controls:2.11%
cases:3.59%
controls:0.86%
—
—
—
—
—
—
cases:25.77%
controls:0.96%
cases:19.14%
controls:3.43%
29
105
470
4860
18
43
483
4932
—
—
—
92
47
265
4860
40
140
169
3946
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
94500-6 [706163]
-1.3e-01
4.1e-01
2.9e+00
—
2.8e+00
1.5e+00
6.5e-01
cases:6.21%
controls:6.99%
cases:6.59%
controls:4.48%
cases:10.38%
controls:0.60%
—
—
cases:10.60%
controls:0.74%
cases:21.85%
controls:5.85%
cases:23.92%
controls:14.12%
31
347
468
4618
33
223
468
4752
52
30
449
4945
—
48
37
405
4931
78
287
279
4620
50
577
159
3509
Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay
5159-9 [3007844]
5159-9 [3007844]
—
—
1.0e+50
1.0e+50
1.0e+50
4.9e+00
2.9e+00
—
—
—
—
cases:3.59%
controls:0.00%
cases:12.18%
controls:0.00%
cases:11.04%
controls:0.00%
cases:12.04%
controls:0.10%
cases:5.26%
controls:0.29%
—
—
18
0
483
4975
61
0
440
4975
50
0
403
4968
43
5
314
4902
11
12
198
4074
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2000-8 [3015377]
4.4e-01
6.8e-01
2.4e+00
—
3.2e+00
1.5e+00
6.7e-01
cases:9.82%
controls:6.53%
cases:4.99%
controls:2.59%
cases:3.39%
controls:0.32%
—
—
cases:7.06%
controls:0.30%
cases:12.04%
controls:2.91%
cases:16.75%
controls:9.32%
49
324
450
4641
25
129
476
4846
17
16
484
4959
—
32
15
421
4953
43
143
314
4764
35
381
174
3705
Morphology [Interpretation] in Bone marrow Narrative
51628-6 [3042111]
51628-6 [3042111]
2.3e+00
—
—
1.0e+50
1.0e+50
—
5.5e+00
cases:1.60%
controls:0.16%
—
—
—
—
cases:17.37%
controls:0.00%
cases:18.54%
controls:0.00%
—
—
cases:25.84%
controls:0.15%
8
8
491
4957
—
—
87
0
414
4975
84
0
369
4968
—
54
6
155
4080
Cytomegalovirus IgM Ab [Units/volume] in Serum or Plasma
7853-5 [3015635]
7853-5 [3015635]
—
—
1.0e+50
1.0e+50
1.0e+50
4.5e+00
3.2e+00
—
—
—
—
cases:2.99%
controls:0.00%
cases:12.18%
controls:0.00%
cases:11.48%
controls:0.00%
cases:11.76%
controls:0.14%
cases:5.26%
controls:0.22%
—
—
15
0
486
4975
61
0
440
4975
52
0
401
4968
42
7
315
4900
11
9
198
4077
Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay
3255-7 [3016407]
3255-7 [3016407]
—
1.5e+00
—
1.0e+50
1.0e+50
4.9e+00
2.8e+00
—
—
cases:1.00%
controls:0.22%
—
—
cases:12.97%
controls:0.00%
cases:14.79%
controls:0.00%
cases:14.29%
controls:0.12%
cases:8.13%
controls:0.54%
—
5
11
496
4964
—
65
0
436
4975
67
0
386
4968
51
6
306
4901
17
22
192
4064
Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection
21363-7 [3020565]
21363-7 [3020565]
2.3e+00
—
—
—
1.0e+50
4.3e+00
3.4e+00
cases:1.00%
controls:0.10%
—
—
—
—
—
—
cases:3.31%
controls:0.00%
cases:6.72%
controls:0.10%
cases:7.66%
controls:0.27%
5
5
494
4960
—
—
—
15
0
438
4968
24
5
333
4902
16
11
193
4075
Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection
92695-6 [37019628]
92695-6 [37019628]
1.9e+00
—
—
—
—
4.0e+00
1.8e+00
cases:1.40%
controls:0.22%
—
—
—
—
—
—
—
—
cases:6.16%
controls:0.12%
cases:4.31%
controls:0.71%
7
11
492
4954
—
—
—
—
22
6
335
4901
9
29
200
4057
Cytomegalovirus IgG Ab [Titer] in Serum or Plasma
22246-3 [3017918]
22246-3 [3017918]
—
—
1.0e+50
1.0e+50
1.0e+50
4.5e+00
3.2e+00
—
—
—
—
cases:2.59%
controls:0.00%
cases:8.58%
controls:0.00%
cases:10.38%
controls:0.00%
cases:10.92%
controls:0.14%
cases:5.26%
controls:0.22%
—
—
13
0
488
4975
43
0
458
4975
47
0
406
4968
39
7
318
4900
11
9
198
4077
Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum
31374-2 [3007080]
31374-2 [3007080]
—
—
1.0e+50
1.0e+50
1.0e+50
4.6e+00
3.0e+00
—
—
—
—
cases:3.19%
controls:0.00%
cases:9.98%
controls:0.00%
cases:9.93%
controls:0.00%
cases:9.52%
controls:0.10%
cases:5.26%
controls:0.27%
—
—
16
0
485
4975
50
0
451
4975
45
0
408
4968
34
5
323
4902
11
11
198
4075
Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma
7852-7 [3010130]
7852-7 [3010130]
—
2.3e+00
1.0e+50
1.0e+50
1.0e+50
4.3e+00
3.3e+00
—
—
cases:1.00%
controls:0.10%
cases:2.40%
controls:0.00%
cases:10.18%
controls:0.00%
cases:16.78%
controls:0.00%
cases:9.52%
controls:0.14%
cases:5.74%
controls:0.22%
—
5
5
496
4970
12
0
489
4975
51
0
450
4975
76
0
377
4968
34
7
323
4900
12
9
197
4077
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
1805-1 [3016417]
4.2e-01
6.6e-01
3.1e+00
—
2.1e+00
2.4e+00
5.8e-01
cases:1.80%
controls:1.19%
cases:1.20%
controls:0.62%
cases:2.20%
controls:0.10%
—
—
cases:1.32%
controls:0.16%
cases:5.88%
controls:0.59%
cases:3.35%
controls:1.91%
9
59
490
4906
6
31
495
4944
11
5
490
4970
—
6
8
447
4960
21
29
336
4878
7
78
202
4008
Bacteria identified in Urine by Culture
630-4 [3026008]
630-4 [3026008]
3.9e-01
2.5e-01
2.7e+00
1.0e+50
3.0e+00
1.8e+00
5.2e-01
cases:8.62%
controls:6.02%
cases:3.59%
controls:2.83%
cases:4.99%
controls:0.34%
cases:2.79%
controls:0.00%
cases:8.39%
controls:0.46%
cases:18.49%
controls:3.44%
cases:15.31%
controls:9.69%
43
299
456
4666
18
141
483
4834
25
17
476
4958
14
0
487
4975
38
23
415
4945
66
169
291
4738
32
396
177
3690
Immunohistochemistry procedure
117617002 [4035726]
117617002 [4035726]
2.2e+00
2.1e+00
—
1.0e+50
—
2.7e+00
2.6e+00
cases:4.01%
controls:0.46%
cases:1.00%
controls:0.12%
—
—
cases:7.19%
controls:0.00%
—
—
cases:5.04%
controls:0.37%
cases:4.31%
controls:0.32%
20
23
479
4942
5
6
496
4969
—
36
0
465
4975
—
18
18
339
4889
9
13
200
4073
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
51486-9 [3029879]
2.3e-02
5.5e-01
2.7e+00
1.0e+50
2.5e+00
2.2e+00
5.8e-01
cases:2.20%
controls:2.16%
cases:2.59%
controls:1.51%
cases:3.39%
controls:0.24%
cases:1.00%
controls:0.00%
cases:3.53%
controls:0.30%
cases:12.32%
controls:1.53%
cases:8.61%
controls:4.99%
11
107
488
4858
13
75
488
4900
17
12
484
4963
5
0
496
4975
16
15
437
4953
44
75
313
4832
18
204
191
3882
Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection
29257-3 [3002482]
29257-3 [3002482]
1.7e+00
—
—
—
1.0e+50
4.3e+00
3.0e+00
cases:1.00%
controls:0.18%
—
—
—
—
—
—
cases:4.42%
controls:0.00%
cases:11.20%
controls:0.16%
cases:9.57%
controls:0.51%
5
9
494
4956
—
—
—
20
0
433
4968
40
8
317
4899
20
21
189
4065
cycloSPORINE [Mass/volume] in Blood
3520-4 [3010375]
3520-4 [3010375]
-1.0e+50
-1.0e+50
—
—
—
3.6e+00
3.7e+00
cases:0.00%
controls:0.12%
cases:0.00%
controls:0.16%
—
—
—
—
—
—
cases:5.60%
controls:0.16%
cases:6.70%
controls:0.17%
0
6
499
4959
0
8
501
4967
—
—
—
20
8
337
4899
14
7
195
4079
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
R91 [45548995]
1.2e+00
1.6e+00
—
—
—
2.7e+00
1.8e+00
cases:2.81%
controls:0.85%
cases:1.80%
controls:0.38%
—
—
—
—
—
—
cases:5.04%
controls:0.35%
cases:5.26%
controls:0.95%
14
42
485
4923
9
19
492
4956
—
—
—
18
17
339
4890
11
39
198
4047
High resolution CT examination of lungs
GD1DD [2001303632]
GD1DD [2001303632]
5.8e-01
—
—
1.0e+50
—
4.1e+00
3.1e+00
cases:1.00%
controls:0.56%
—
—
—
—
cases:1.40%
controls:0.00%
—
—
cases:12.32%
controls:0.22%
cases:8.61%
controls:0.42%
5
28
494
4937
—
—
7
0
494
4975
—
44
11
313
4896
18
17
191
4069
Tacrolimus [Mass/volume] in Blood
11253-2 [3026250]
11253-2 [3026250]
—
—
—
—
—
3.8e+00
3.4e+00
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.12%
cases:4.31%
controls:0.15%
—
—
—
—
—
19
6
338
4901
9
6
200
4080
Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection
23826-1 [3012477]
23826-1 [3012477]
2.1e+00
—
—
—
1.0e+50
4.0e+00
3.2e+00
cases:1.00%
controls:0.12%
—
—
—
—
—
—
cases:3.53%
controls:0.00%
cases:7.00%
controls:0.14%
cases:8.13%
controls:0.34%
5
6
494
4959
—
—
—
16
0
437
4968
25
7
332
4900
17
14
192
4072
Pediatric Medicine
37 [38004477]
37 [38004477]
-3.8e-02
—
1.8e+00
—
2.2e+00
1.6e+00
1.6e+00
cases:1.20%
controls:1.25%
—
—
cases:1.40%
controls:0.24%
—
—
cases:2.21%
controls:0.24%
cases:3.36%
controls:0.67%
cases:5.26%
controls:1.15%
6
62
493
4903
—
7
12
494
4963
—
10
12
443
4956
12
33
345
4874
11
47
198
4039
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
1.5e-01
2.5e-01
2.6e+00
—
3.0e+00
1.6e+00
4.4e-01
cases:18.44%
controls:16.29%
cases:10.78%
controls:8.62%
cases:13.77%
controls:1.17%
—
—
cases:18.76%
controls:1.11%
cases:31.37%
controls:8.78%
cases:29.67%
controls:21.41%
92
809
407
4156
54
429
447
4546
69
58
432
4917
—
85
55
368
4913
112
431
245
4476
62
875
147
3211
Base excess in Arterial blood by calculation
1925-7 [3003396]
1925-7 [3003396]
8.2e-01
1.5e-01
2.2e+00
—
3.2e+00
1.8e+00
2.8e-01
cases:3.41%
controls:1.53%
cases:1.00%
controls:0.86%
cases:2.40%
controls:0.28%
—
—
cases:2.43%
controls:0.10%
cases:5.32%
controls:0.94%
cases:4.31%
controls:3.30%
17
76
482
4889
5
43
496
4932
12
14
489
4961
—
11
5
442
4963
19
46
338
4861
9
135
200
3951
Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection
34645-2 [3031478]
34645-2 [3031478]
—
—
—
—
1.0e+50
4.1e+00
3.0e+00
—
—
—
—
—
—
—
—
cases:3.53%
controls:0.00%
cases:9.24%
controls:0.16%
cases:7.66%
controls:0.42%
—
—
—
—
16
0
437
4968
33
8
324
4899
16
17
193
4069
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
2.1e-01
2.8e-01
2.6e+00
1.0e+50
2.5e+00
2.0e+00
4.1e-01
cases:7.21%
controls:5.92%
cases:4.19%
controls:3.20%
cases:6.59%
controls:0.50%
cases:2.20%
controls:0.00%
cases:5.74%
controls:0.50%
cases:20.73%
controls:3.48%
cases:14.83%
controls:10.40%
36
294
463
4671
21
159
480
4816
33
25
468
4950
11
0
490
4975
26
25
427
4943
74
171
283
4736
31
425
178
3661
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
1.8e-01
2.6e-01
2.5e+00
1.0e+50
2.8e+00
1.8e+00
4.2e-01
cases:7.62%
controls:6.47%
cases:4.79%
controls:3.74%
cases:7.19%
controls:0.64%
cases:4.39%
controls:0.00%
cases:7.73%
controls:0.52%
cases:20.45%
controls:4.12%
cases:16.75%
controls:11.65%
38
321
461
4644
24
186
477
4789
36
32
465
4943
22
0
479
4975
35
26
418
4942
73
202
284
4705
35
476
174
3610
pH of Arterial blood
2744-1 [3019977]
2744-1 [3019977]
7.7e-01
1.7e-01
2.1e+00
—
3.1e+00
1.8e+00
4.2e-01
cases:3.21%
controls:1.51%
cases:1.00%
controls:0.84%
cases:2.20%
controls:0.26%
—
—
cases:2.21%
controls:0.10%
cases:5.32%
controls:0.96%
cases:4.78%
controls:3.21%
16
75
483
4890
5
42
496
4933
11
13
490
4962
—
10
5
443
4963
19
47
338
4860
10
131
199
3955
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
30383-4 [3000850]
2.2e-01
6.7e-02
2.8e+00
1.0e+50
2.4e+00
1.8e+00
3.1e-01
cases:5.61%
controls:4.55%
cases:2.00%
controls:1.87%
cases:3.79%
controls:0.24%
cases:1.20%
controls:0.00%
cases:2.65%
controls:0.24%
cases:10.92%
controls:1.98%
cases:7.66%
controls:5.73%
28
226
471
4739
10
93
491
4882
19
12
482
4963
6
0
495
4975
12
12
441
4956
39
97
318
4810
16
234
193
3852
metronidazole; oral, rectal
P01AB01 [21604857]
P01AB01 [21604857]
3.0e-01
8.8e-01
2.6e+00
—
2.4e+00
2.0e+00
7.8e-01
cases:8.22%
controls:6.24%
cases:2.99%
controls:1.27%
cases:2.20%
controls:0.16%
—
—
cases:1.10%
controls:0.10%
cases:9.52%
controls:1.45%
cases:11.00%
controls:5.38%
41
310
458
4655
15
63
486
4912
11
8
490
4967
—
5
5
448
4963
34
71
323
4836
23
220
186
3866
Antithrombin actual/normal in Platelet poor plasma by Chromogenic method
27811-9 [3000515]
27811-9 [3000515]
—
—
—
1.0e+50
1.0e+50
4.5e+00
2.5e+00
—
—
—
—
—
—
cases:5.39%
controls:0.00%
cases:8.17%
controls:0.00%
cases:10.36%
controls:0.12%
cases:6.22%
controls:0.56%
—
—
—
27
0
474
4975
37
0
416
4968
37
6
320
4901
13
23
196
4063
Reticulocyte production index
31111-8 [3000012]
31111-8 [3000012]
—
—
1.0e+50
1.0e+50
—
4.3e+00
2.7e+00
—
—
—
—
cases:3.19%
controls:0.00%
cases:3.59%
controls:0.00%
—
—
cases:7.28%
controls:0.10%
cases:6.22%
controls:0.47%
—
—
16
0
485
4975
18
0
483
4975
—
26
5
331
4902
13
19
196
4067
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
51485-1 [3030306]
-1.0e-01
3.8e-01
2.5e+00
1.0e+50
2.5e+00
2.0e+00
3.4e-01
cases:2.00%
controls:2.22%
cases:2.40%
controls:1.65%
cases:3.39%
controls:0.30%
cases:1.00%
controls:0.00%
cases:3.53%
controls:0.30%
cases:11.76%
controls:1.69%
cases:7.66%
controls:5.58%
10
110
489
4855
12
82
489
4893
17
15
484
4960
5
0
496
4975
16
15
437
4953
42
83
315
4824
16
228
193
3858
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
47210-0 [3048773]
-1.8e-01
1.0e-01
1.1e+00
3.6e+00
2.2e+00
2.1e-01
-3.9e-02
cases:26.85%
controls:30.57%
cases:16.97%
controls:15.56%
cases:5.19%
controls:1.71%
cases:3.59%
controls:0.10%
cases:13.02%
controls:1.59%
cases:19.61%
controls:16.49%
cases:32.54%
controls:33.41%
134
1518
365
3447
85
774
416
4201
26
85
475
4890
18
5
483
4970
59
79
394
4889
70
809
287
4098
68
1365
141
2721
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
2703-7 [3027801]
8.3e-01
1.7e-01
2.1e+00
—
3.2e+00
1.7e+00
4.7e-01
cases:3.41%
controls:1.51%
cases:1.00%
controls:0.84%
cases:2.20%
controls:0.28%
—
—
cases:2.43%
controls:0.10%
cases:4.76%
controls:0.94%
cases:5.26%
controls:3.35%
17
75
482
4890
5
42
496
4933
11
14
490
4961
—
11
5
442
4963
17
46
340
4861
11
137
198
3949
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
2019-8 [3027946]
8.3e-01
1.7e-01
2.1e+00
—
3.2e+00
1.7e+00
4.7e-01
cases:3.41%
controls:1.51%
cases:1.00%
controls:0.84%
cases:2.20%
controls:0.28%
—
—
cases:2.43%
controls:0.10%
cases:4.76%
controls:0.94%
cases:5.26%
controls:3.35%
17
75
482
4890
5
42
496
4933
11
14
490
4961
—
11
5
442
4963
17
46
340
4861
11
137
198
3949
Abdominal ultrasound examination
JN3AE [2001305555]
JN3AE [2001305555]
9.3e-01
1.8e+00
—
1.0e+50
—
3.1e+00
2.0e+00
cases:2.81%
controls:1.13%
cases:2.00%
controls:0.34%
—
—
cases:2.40%
controls:0.00%
—
—
cases:8.40%
controls:0.43%
cases:9.57%
controls:1.35%
14
56
485
4909
10
17
491
4958
—
12
0
489
4975
—
30
21
327
4886
20
55
189
4031
enoxaparin; parenteral
B01AB05 [21600976]
B01AB05 [21600976]
5.7e-01
7.1e-01
—
—
3.2e+00
2.5e+00
1.1e+00
cases:7.82%
controls:4.59%
cases:2.59%
controls:1.29%
—
—
—
—
cases:4.19%
controls:0.18%
cases:12.04%
controls:1.08%
cases:10.53%
controls:3.65%
39
228
460
4737
13
64
488
4911
—
—
19
9
434
4959
43
53
314
4854
22
149
187
3937
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
1.7e-01
2.5e-01
2.3e+00
—
3.0e+00
1.4e+00
3.3e-01
cases:20.24%
controls:17.66%
cases:11.38%
controls:9.07%
cases:12.18%
controls:1.31%
—
—
cases:20.09%
controls:1.19%
cases:30.25%
controls:9.25%
cases:28.71%
controls:22.37%
101
877
398
4088
57
451
444
4524
61
65
440
4910
—
91
59
362
4909
108
454
249
4453
60
914
149
3172
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
9.4e-02
1.2e-01
2.6e+00
1.0e+50
2.4e+00
1.8e+00
5.6e-01
cases:5.61%
controls:5.14%
cases:3.19%
controls:2.85%
cases:5.19%
controls:0.40%
cases:1.60%
controls:0.00%
cases:4.86%
controls:0.46%
cases:15.97%
controls:2.95%
cases:12.92%
controls:7.83%
28
255
471
4710
16
142
485
4833
26
20
475
4955
8
0
493
4975
22
23
431
4945
57
145
300
4762
27
320
182
3766
Bronchial lavation
TGC00 [2001303585]
TGC00 [2001303585]
—
—
1.0e+50
—
1.0e+50
4.2e+00
2.6e+00
—
—
—
—
cases:1.20%
controls:0.00%
—
—
cases:1.55%
controls:0.00%
cases:6.16%
controls:0.10%
cases:3.35%
controls:0.24%
—
—
6
0
495
4975
—
7
0
446
4968
22
5
335
4902
7
10
202
4076
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
1.9e-01
7.3e-02
2.5e+00
1.0e+50
2.4e+00
1.9e+00
5.0e-01
cases:6.21%
controls:5.20%
cases:3.19%
controls:2.97%
cases:5.39%
controls:0.48%
cases:1.60%
controls:0.00%
cases:5.08%
controls:0.48%
cases:18.21%
controls:3.18%
cases:13.40%
controls:8.57%
31
258
468
4707
16
148
485
4827
27
24
474
4951
8
0
493
4975
23
24
430
4944
65
156
292
4751
28
350
181
3736
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-2.5e-01
-2.8e-01
7.9e-01
—
—
3.2e+00
3.5e+00
cases:20.04%
controls:24.29%
cases:5.79%
controls:7.50%
cases:1.80%
controls:0.82%
—
—
—
—
cases:13.17%
controls:0.59%
cases:25.36%
controls:1.00%
100
1206
399
3759
29
373
472
4602
9
41
492
4934
—
—
47
29
310
4878
53
41
156
4045
Infiltration anesthesia
WX110 [2001310767]
WX110 [2001310767]
2.8e-01
1.5e-01
2.0e+00
—
2.1e+00
1.8e+00
8.2e-01
cases:20.44%
controls:16.31%
cases:6.99%
controls:6.09%
cases:5.99%
controls:0.82%
—
—
cases:5.74%
controls:0.76%
cases:28.29%
controls:6.38%
cases:33.97%
controls:18.50%
102
810
397
4155
35
303
466
4672
30
41
471
4934
—
26
38
427
4930
101
313
256
4594
71
756
138
3330
Emergency Medicine
93 [38004510]
93 [38004510]
2.7e-01
4.8e-01
3.2e+00
—
2.1e+00
1.3e+00
3.9e-01
cases:17.64%
controls:14.02%
cases:12.38%
controls:8.04%
cases:19.16%
controls:0.94%
—
—
cases:9.27%
controls:1.21%
cases:27.45%
controls:9.07%
cases:30.62%
controls:22.98%
88
696
411
4269
62
400
439
4575
96
47
405
4928
—
42
60
411
4908
98
445
259
4462
64
939
145
3147
tacrolimus; oral, parenteral
L04AD02 [21603925]
L04AD02 [21603925]
—
—
—
—
—
3.8e+00
2.8e+00
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.12%
cases:2.87%
controls:0.17%
—
—
—
—
—
19
6
338
4901
6
7
203
4079
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
76080-1 [46235759]
1.5e+00
1.4e+00
—
1.0e+50
1.0e+50
3.4e+00
1.7e+00
cases:2.00%
controls:0.44%
cases:1.20%
controls:0.30%
—
—
cases:1.60%
controls:0.00%
cases:4.42%
controls:0.00%
cases:8.96%
controls:0.33%
cases:6.22%
controls:1.15%
10
22
489
4943
6
15
495
4960
—
8
0
493
4975
20
0
433
4968
32
16
325
4891
13
47
196
4039
FEV1/FVC
19926-5 [3011505]
19926-5 [3011505]
5.5e-01
1.4e+00
—
—
—
2.6e+00
2.6e+00
cases:3.21%
controls:1.87%
cases:2.40%
controls:0.60%
—
—
—
—
—
—
cases:7.56%
controls:0.59%
cases:12.44%
controls:1.00%
16
93
483
4872
12
30
489
4945
—
—
—
27
29
330
4878
26
41
183
4045
FEV1
20150-9 [3024653]
20150-9 [3024653]
5.5e-01
1.4e+00
—
—
—
2.6e+00
2.6e+00
cases:3.21%
controls:1.87%
cases:2.40%
controls:0.60%
—
—
—
—
—
—
cases:7.56%
controls:0.59%
cases:12.44%
controls:1.00%
16
93
483
4872
12
30
489
4945
—
—
—
27
29
330
4878
26
41
183
4045
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
19870-5 [3020158]
5.5e-01
1.4e+00
—
—
—
2.6e+00
2.6e+00
cases:3.21%
controls:1.87%
cases:2.40%
controls:0.60%
—
—
—
—
—
—
cases:7.56%
controls:0.59%
cases:12.44%
controls:1.00%
16
93
483
4872
12
30
489
4945
—
—
—
27
29
330
4878
26
41
183
4045
Extended examination of mouth
SAA03 [2001310276]
SAA03 [2001310276]
2.3e-01
1.1e-01
1.8e+00
—
3.3e+00
2.2e+00
1.2e+00
cases:8.42%
controls:6.81%
cases:1.60%
controls:1.43%
cases:1.00%
controls:0.16%
—
—
cases:3.53%
controls:0.14%
cases:10.64%
controls:1.30%
cases:15.79%
controls:5.36%
42
338
457
4627
8
71
493
4904
5
8
496
4967
—
16
7
437
4961
38
64
319
4843
33
219
176
3867
Osmolality of Urine
2695-5 [3026782]
2695-5 [3026782]
6.6e-02
-1.0e-01
2.7e+00
—
2.2e+00
1.7e+00
7.1e-01
cases:5.21%
controls:4.89%
cases:1.60%
controls:1.77%
cases:3.59%
controls:0.26%
—
—
cases:2.43%
controls:0.26%
cases:10.08%
controls:1.94%
cases:9.09%
controls:4.67%
26
243
473
4722
8
88
493
4887
18
13
483
4962
—
11
13
442
4955
36
95
321
4812
19
191
190
3895
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
4542-7 [3012336]
3.8e-01
1.9e+00
—
1.0e+50
—
3.3e+00
1.5e+00
cases:1.40%
controls:0.97%
cases:2.40%
controls:0.38%
—
—
cases:4.79%
controls:0.00%
—
—
cases:9.24%
controls:0.37%
cases:5.74%
controls:1.40%
7
48
492
4917
12
19
489
4956
—
24
0
477
4975
—
33
18
324
4889
12
57
197
4029
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
14798-3 [3022948]
4.9e-01
1.0e+00
3.5e+00
—
—
1.2e+00
8.8e-01
cases:4.41%
controls:2.76%
cases:4.79%
controls:1.81%
cases:5.79%
controls:0.18%
—
—
—
—
cases:5.88%
controls:1.83%
cases:11.48%
controls:5.09%
22
137
477
4828
24
90
477
4885
29
9
472
4966
—
—
21
90
336
4817
24
208
185
3878
Extensive high resolution CT examination of lungs
GD1ED [2001303637]
GD1ED [2001303637]
1.3e+00
—
—
—
—
3.8e+00
2.8e+00
cases:1.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:4.20%
controls:0.10%
cases:2.87%
controls:0.17%
5
14
494
4951
—
—
—
—
15
5
342
4902
6
7
203
4079
Respiratory and circulatory monitoring
WX700 [2001310817]
WX700 [2001310817]
4.5e-01
—
2.2e+00
—
2.4e+00
2.0e+00
—
cases:4.01%
controls:2.60%
—
—
cases:1.20%
controls:0.14%
—
—
cases:1.10%
controls:0.10%
cases:4.48%
controls:0.61%
—
—
20
129
479
4836
—
6
7
495
4968
—
5
5
448
4963
16
30
341
4877
—
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
60517-0 [40763571]
3.4e-01
9.7e-01
3.4e+00
—
—
1.3e+00
9.8e-01
cases:3.41%
controls:2.44%
cases:3.99%
controls:1.55%
cases:4.99%
controls:0.18%
—
—
—
—
cases:5.60%
controls:1.67%
cases:11.00%
controls:4.43%
17
121
482
4844
20
77
481
4898
25
9
476
4966
—
—
20
82
337
4825
23
181
186
3905
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
2039-6 [3003785]
1.7e+00
2.3e+00
—
—
—
2.6e+00
—
cases:4.41%
controls:0.81%
cases:3.39%
controls:0.36%
—
—
—
—
—
—
cases:3.08%
controls:0.24%
—
—
22
40
477
4925
17
18
484
4957
—
—
—
11
12
346
4895
—
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
14647-2 [3019900]
-1.9e-01
2.3e-02
1.2e+00
3.4e+00
2.0e+00
-1.5e-01
-1.5e-01
cases:28.46%
controls:32.41%
cases:19.16%
controls:18.81%
cases:6.59%
controls:2.09%
cases:2.79%
controls:0.10%
cases:13.69%
controls:2.07%
cases:18.21%
controls:20.54%
cases:37.32%
controls:40.99%
142
1609
357
3356
96
936
405
4039
33
104
468
4871
14
5
487
4970
62
103
391
4865
65
1008
292
3899
78
1675
131
2411
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
2472-9 [3028026]
5.9e-01
1.4e+00
—
1.0e+50
—
3.0e+00
2.2e+00
cases:1.40%
controls:0.79%
cases:2.20%
controls:0.54%
—
—
cases:8.58%
controls:0.00%
—
—
cases:7.56%
controls:0.41%
cases:7.66%
controls:0.95%
7
39
492
4926
11
27
490
4948
—
43
0
458
4975
—
27
20
330
4887
16
39
193
4047
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
3034-6 [3004789]
2.7e-01
9.8e-01
3.4e+00
—
—
1.3e+00
9.2e-01
cases:3.41%
controls:2.62%
cases:4.19%
controls:1.61%
cases:4.99%
controls:0.18%
—
—
—
—
cases:6.16%
controls:1.79%
cases:11.48%
controls:4.89%
17
130
482
4835
21
80
480
4895
25
9
476
4966
—
—
22
88
335
4819
24
200
185
3886
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2324-2 [3026910]
2.3e-01
5.6e-01
2.3e+00
—
2.5e+00
1.2e+00
4.6e-01
cases:16.83%
controls:13.88%
cases:9.98%
controls:5.95%
cases:7.78%
controls:0.82%
—
—
cases:6.62%
controls:0.58%
cases:19.61%
controls:6.97%
cases:24.88%
controls:17.28%
84
689
415
4276
50
296
451
4679
39
41
462
4934
—
30
29
423
4939
70
342
287
4565
52
706
157
3380
ECG with 12 standard connections
XF400 [2001303368]
XF400 [2001303368]
-6.3e-02
8.1e-01
2.5e+00
—
2.3e+00
1.8e+00
7.9e-01
cases:2.40%
controls:2.56%
cases:2.20%
controls:0.98%
cases:1.20%
controls:0.10%
—
—
cases:1.32%
controls:0.14%
cases:3.36%
controls:0.57%
cases:4.31%
controls:2.01%
12
127
487
4838
11
49
490
4926
6
5
495
4970
—
6
7
447
4961
12
28
345
4879
9
82
200
4004
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
TPH15 [2001309600]
9.2e-01
—
1.0e+50
1.0e+50
1.0e+50
4.6e+00
1.9e+00
cases:1.20%
controls:0.48%
—
—
cases:4.79%
controls:0.00%
cases:2.20%
controls:0.00%
cases:6.18%
controls:0.00%
cases:15.69%
controls:0.18%
cases:4.31%
controls:0.66%
6
24
493
4941
—
24
0
477
4975
11
0
490
4975
28
0
425
4968
56
9
301
4898
9
27
200
4059
Lysozyme [Mass/volume] in Serum or Plasma
2589-0 [3012110]
2589-0 [3012110]
1.4e+00
2.3e+00
1.0e+50
1.0e+50
1.0e+50
2.3e+00
1.9e+00
cases:1.60%
controls:0.38%
cases:1.20%
controls:0.12%
cases:1.80%
controls:0.00%
cases:5.99%
controls:0.00%
cases:3.75%
controls:0.00%
cases:1.68%
controls:0.16%
cases:3.35%
controls:0.54%
8
19
491
4946
6
6
495
4969
9
0
492
4975
30
0
471
4975
17
0
436
4968
6
8
351
4899
7
22
202
4064
Segmented neutrophils/Leukocytes in Blood
26505-8 [3017354]
26505-8 [3017354]
2.6e+00
—
1.0e+50
1.0e+50
1.0e+50
—
3.9e+00
cases:1.60%
controls:0.12%
—
—
cases:5.39%
controls:0.00%
cases:4.99%
controls:0.00%
cases:5.08%
controls:0.00%
—
—
cases:5.74%
controls:0.12%
8
6
491
4959
—
27
0
474
4975
25
0
476
4975
23
0
430
4968
—
12
5
197
4081
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
29760-6 [3005772]
4.6e-01
1.5e+00
—
1.0e+50
—
3.0e+00
2.0e+00
cases:3.21%
controls:2.05%
cases:2.20%
controls:0.52%
—
—
cases:3.99%
controls:0.00%
—
—
cases:14.29%
controls:0.79%
cases:17.22%
controls:2.72%
16
102
483
4863
11
26
490
4949
—
20
0
481
4975
—
51
39
306
4868
36
111
173
3975
pH of Urine
2756-5 [3015736]
2756-5 [3015736]
-1.3e-01
-3.6e-02
2.3e+00
1.0e+50
2.9e+00
1.3e+00
1.1e-01
cases:7.62%
controls:8.58%
cases:4.39%
controls:4.54%
cases:5.79%
controls:0.64%
cases:5.19%
controls:0.00%
cases:9.49%
controls:0.58%
cases:16.25%
controls:4.81%
cases:14.83%
controls:13.49%
38
426
461
4539
22
226
479
4749
29
32
472
4943
26
0
475
4975
43
29
410
4939
58
236
299
4671
31
551
178
3535
nystatin; vaginal
G01AA01 [21602363]
G01AA01 [21602363]
7.6e-01
-1.0e+50
—
—
—
3.7e+00
2.7e+00
cases:1.20%
controls:0.56%
cases:0.00%
controls:0.12%
—
—
—
—
—
—
cases:4.76%
controls:0.12%
cases:5.74%
controls:0.39%
6
28
493
4937
0
6
501
4969
—
—
—
17
6
340
4901
12
16
197
4070
nystatin
D01AA01 [21601911]
D01AA01 [21601911]
7.6e-01
-1.0e+50
—
—
—
3.7e+00
2.7e+00
cases:1.20%
controls:0.56%
cases:0.00%
controls:0.12%
—
—
—
—
—
—
cases:4.76%
controls:0.12%
cases:5.74%
controls:0.39%
6
28
493
4937
0
6
501
4969
—
—
—
17
6
340
4901
12
16
197
4070
metronidazole and furazolidone
P01AB51 [45893518]
P01AB51 [45893518]
7.6e-01
-1.0e+50
—
—
—
3.7e+00
2.7e+00
cases:1.20%
controls:0.56%
cases:0.00%
controls:0.12%
—
—
—
—
—
—
cases:4.76%
controls:0.12%
cases:5.74%
controls:0.39%
6
28
493
4937
0
6
501
4969
—
—
—
17
6
340
4901
12
16
197
4070
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
20454-5 [3014051]
1.7e-01
3.1e-01
2.4e+00
1.0e+50
2.6e+00
1.4e+00
-4.9e-02
cases:4.61%
controls:3.93%
cases:3.19%
controls:2.35%
cases:3.39%
controls:0.32%
cases:3.39%
controls:0.00%
cases:4.86%
controls:0.36%
cases:10.64%
controls:2.83%
cases:8.61%
controls:9.01%
23
195
476
4770
16
117
485
4858
17
16
484
4959
17
0
484
4975
22
18
431
4950
38
139
319
4768
18
368
191
3718
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
-1.2e-02
2.0e-02
2.3e+00
1.0e+50
2.9e+00
1.2e+00
-4.7e-03
cases:10.42%
controls:10.53%
cases:6.19%
controls:6.07%
cases:7.58%
controls:0.80%
cases:5.59%
controls:0.00%
cases:11.04%
controls:0.68%
cases:19.33%
controls:6.70%
cases:19.14%
controls:19.21%
52
523
447
4442
31
302
470
4673
38
40
463
4935
28
0
473
4975
50
34
403
4934
69
329
288
4578
40
785
169
3301
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
-5.7e-02
1.0e-02
2.3e+00
1.0e+50
2.9e+00
1.2e+00
-3.1e-02
cases:9.82%
controls:10.33%
cases:5.99%
controls:5.93%
cases:7.39%
controls:0.82%
cases:5.59%
controls:0.00%
cases:11.26%
controls:0.68%
cases:19.05%
controls:6.60%
cases:18.66%
controls:19.14%
49
513
450
4452
30
295
471
4680
37
41
464
4934
28
0
473
4975
51
34
402
4934
68
324
289
4583
39
782
170
3304
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
-3.9e-02
-1.5e-02
2.3e+00
1.0e+50
2.9e+00
1.2e+00
7.9e-03
cases:9.82%
controls:10.17%
cases:5.79%
controls:5.87%
cases:7.39%
controls:0.82%
cases:5.59%
controls:0.00%
cases:10.82%
controls:0.66%
cases:19.05%
controls:6.52%
cases:19.14%
controls:19.02%
49
505
450
4460
29
292
472
4683
37
41
464
4934
28
0
473
4975
49
33
404
4935
68
320
289
4587
40
777
169
3309
Supine thorax X-ray examination
GD1QA [2001303648]
GD1QA [2001303648]
8.6e-02
-1.0e-01
2.5e+00
—
2.0e+00
1.8e+00
9.8e-02
cases:2.61%
controls:2.40%
cases:1.00%
controls:1.11%
cases:2.00%
controls:0.16%
—
—
cases:1.77%
controls:0.24%
cases:8.40%
controls:1.45%
cases:5.26%
controls:4.80%
13
119
486
4846
5
55
496
4920
10
8
491
4967
—
8
12
445
4956
30
71
327
4836
11
196
198
3890
allopurinol; oral, parenteral
M04AA01 [21604131]
M04AA01 [21604131]
7.2e-01
6.0e-01
6.5e-01
—
2.6e+00
1.8e+00
1.2e+00
cases:6.81%
controls:3.42%
cases:5.19%
controls:2.91%
cases:1.80%
controls:0.94%
—
—
cases:11.92%
controls:0.99%
cases:16.25%
controls:3.26%
cases:14.35%
controls:4.70%
34
170
465
4795
26
145
475
4830
9
47
492
4928
—
54
49
399
4919
58
160
299
4747
30
192
179
3894
Leukocyte morphology finding [Identifier] in Blood
11156-7 [3008757]
11156-7 [3008757]
2.4e+00
—
1.0e+50
1.0e+50
1.0e+50
—
3.9e+00
cases:2.00%
controls:0.18%
—
—
cases:4.79%
controls:0.00%
cases:4.39%
controls:0.00%
cases:4.86%
controls:0.00%
—
—
cases:6.70%
controls:0.15%
10
9
489
4956
—
24
0
477
4975
22
0
479
4975
22
0
431
4968
—
14
6
195
4080
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
NK6QA [2001308500]
—
—
—
—
—
3.2e+00
3.1e+00
—
—
—
—
—
—
—
—
—
—
cases:3.92%
controls:0.16%
cases:12.44%
controls:0.66%
—
—
—
—
—
14
8
343
4899
26
27
183
4059
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
50949-7 [3029937]
-1.5e-01
-2.7e-01
2.2e+00
1.0e+50
3.1e+00
9.3e-01
-1.1e-01
cases:5.81%
controls:6.69%
cases:2.79%
controls:3.62%
cases:4.19%
controls:0.48%
cases:2.20%
controls:0.00%
cases:6.40%
controls:0.30%
cases:9.24%
controls:3.85%
cases:9.57%
controls:10.55%
29
332
470
4633
14
180
487
4795
21
24
480
4951
11
0
490
4975
29
15
424
4953
33
189
324
4718
20
431
189
3655
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
6.1e-01
4.6e-01
2.2e+00
—
—
2.8e+00
1.2e+00
cases:4.61%
controls:2.56%
cases:1.40%
controls:0.88%
cases:1.20%
controls:0.14%
—
—
—
—
cases:15.69%
controls:1.12%
cases:9.57%
controls:2.96%
23
127
476
4838
7
44
494
4931
6
7
495
4968
—
—
56
55
301
4852
20
121
189
3965
Thrombocytopenia, unspecified
D69.6 [45581327]
D69.6 [45581327]
2.6e+00
1.0e+50
1.0e+50
1.0e+50
1.0e+50
3.5e+00
—
cases:1.40%
controls:0.10%
cases:1.60%
controls:0.00%
cases:5.99%
controls:0.00%
cases:1.60%
controls:0.00%
cases:2.65%
controls:0.00%
cases:3.36%
controls:0.10%
—
—
7
5
492
4960
8
0
493
4975
30
0
471
4975
8
0
493
4975
12
0
441
4968
12
5
345
4902
—
Granulocytes/Leukocytes in Blood
30395-8 [3035933]
30395-8 [3035933]
6.9e-01
—
—
1.0e+50
—
3.0e+00
3.1e+00
cases:1.20%
controls:0.60%
—
—
—
—
cases:1.40%
controls:0.00%
—
—
cases:3.64%
controls:0.18%
cases:3.83%
controls:0.17%
6
30
493
4935
—
—
7
0
494
4975
—
13
9
344
4898
8
7
201
4079
Sepsis, unspecified
A41.9 [45585911]
A41.9 [45585911]
—
—
—
—
—
4.0e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:7.56%
controls:0.14%
cases:3.83%
controls:0.49%
—
—
—
—
—
27
7
330
4900
8
20
201
4066
triamcinolone and antiinfectives
S02CA04 [21605176]
S02CA04 [21605176]
6.6e-01
—
—
—
—
3.6e+00
2.6e+00
cases:1.20%
controls:0.62%
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.14%
cases:5.74%
controls:0.47%
6
31
493
4934
—
—
—
—
17
7
340
4900
12
19
197
4067
Norovirus RNA [Presence] in Stool by NAA with probe detection
7974-9 [3008909]
7974-9 [3008909]
1.3e+00
—
—
—
—
3.6e+00
2.5e+00
cases:1.00%
controls:0.28%
—
—
—
—
—
—
—
—
cases:9.52%
controls:0.29%
cases:8.13%
controls:0.73%
5
14
494
4951
—
—
—
—
34
14
323
4893
17
30
192
4056
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
9.0e-02
2.5e-01
1.2e+00
2.7e+00
1.5e+00
7.0e-01
-1.7e-01
cases:65.13%
controls:63.06%
cases:61.08%
controls:55.12%
cases:47.70%
controls:22.27%
cases:14.17%
controls:1.09%
cases:56.51%
controls:22.38%
cases:73.11%
controls:57.39%
cases:70.81%
controls:74.13%
325
3131
174
1834
306
2742
195
2233
239
1108
262
3867
71
54
430
4921
256
1112
197
3856
261
2816
96
2091
148
3029
61
1057
Band form neutrophils/Leukocytes in Blood
26508-2 [3004809]
26508-2 [3004809]
2.3e+00
—
—
1.0e+50
1.0e+50
—
3.7e+00
cases:2.20%
controls:0.22%
—
—
—
—
cases:6.39%
controls:0.00%
cases:7.73%
controls:0.00%
—
—
cases:7.66%
controls:0.20%
11
11
488
4954
—
—
32
0
469
4975
35
0
418
4968
—
16
8
193
4078
Thorax CT examination
GD1AD [2001303618]
GD1AD [2001303618]
—
—
—
—
—
3.6e+00
2.4e+00
—
—
—
—
—
—
—
—
—
—
cases:7.00%
controls:0.20%
cases:6.22%
controls:0.61%
—
—
—
—
—
25
10
332
4897
13
25
196
4061
Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]
34548-8 [3045783]
-2.7e-01
-1.0e-01
2.2e+00
—
2.7e+00
1.1e+00
1.4e-01
cases:3.81%
controls:4.93%
cases:1.80%
controls:1.99%
cases:2.00%
controls:0.22%
—
—
cases:2.87%
controls:0.20%
cases:3.92%
controls:1.37%
cases:3.35%
controls:2.91%
19
245
480
4720
9
99
492
4876
10
11
491
4964
—
13
10
440
4958
14
67
343
4840
7
119
202
3967
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
53292-9 [3041096]
1.3e-01
2.7e-01
2.6e+00
1.0e+50
2.3e+00
1.1e+00
1.0e-01
cases:6.21%
controls:5.52%
cases:3.59%
controls:2.75%
cases:3.99%
controls:0.32%
cases:1.20%
controls:0.00%
cases:2.87%
controls:0.28%
cases:8.12%
controls:2.91%
cases:9.57%
controls:8.71%
31
274
468
4691
18
137
483
4838
20
16
481
4959
6
0
495
4975
13
14
440
4954
29
143
328
4764
20
356
189
3730
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
3209-4 [3019250]
—
—
—
1.0e+50
1.0e+50
4.1e+00
1.9e+00
—
—
—
—
—
—
cases:4.39%
controls:0.00%
cases:6.84%
controls:0.00%
cases:5.60%
controls:0.10%
cases:3.83%
controls:0.59%
—
—
—
22
0
479
4975
31
0
422
4968
20
5
337
4902
8
24
201
4062
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
6598-7 [3019800]
1.5e-02
3.4e-01
2.5e+00
—
2.6e+00
9.4e-01
3.5e-01
cases:9.82%
controls:9.69%
cases:6.19%
controls:4.50%
cases:6.59%
controls:0.60%
—
—
cases:5.52%
controls:0.44%
cases:11.48%
controls:4.83%
cases:16.27%
controls:12.09%
49
481
450
4484
31
224
470
4751
33
30
468
4945
—
25
22
428
4946
41
237
316
4670
34
494
175
3592
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
620-5 [3007853]
-1.3e-01
2.7e-01
—
—
2.4e+00
2.5e+00
9.9e-01
cases:2.00%
controls:2.28%
cases:1.00%
controls:0.76%
—
—
—
—
cases:2.43%
controls:0.22%
cases:12.61%
controls:1.14%
cases:7.18%
controls:2.79%
10
113
489
4852
5
38
496
4937
—
—
11
11
442
4957
45
56
312
4851
15
114
194
3972
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
5794-3 [3011397]
-4.1e-01
-3.7e-01
1.9e+00
1.0e+50
2.9e+00
1.1e+00
-2.2e-01
cases:3.21%
controls:4.75%
cases:2.20%
controls:3.14%
cases:2.99%
controls:0.44%
cases:3.19%
controls:0.00%
cases:6.62%
controls:0.38%
cases:9.24%
controls:3.38%
cases:7.18%
controls:8.81%
16
236
483
4729
11
156
490
4819
15
22
486
4953
16
0
485
4975
30
19
423
4949
33
166
324
4741
15
360
194
3726
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
1.1e-01
6.6e-01
2.5e+00
—
2.2e+00
5.5e-01
1.6e-01
cases:21.84%
controls:20.00%
cases:18.36%
controls:10.41%
cases:17.37%
controls:1.73%
—
—
cases:10.82%
controls:1.31%
cases:16.81%
controls:10.45%
cases:27.27%
controls:24.18%
109
993
390
3972
92
518
409
4457
87
86
414
4889
—
49
65
404
4903
60
513
297
4394
57
988
152
3098
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
54067-4 [3051552]
8.6e-01
1.3e+00
—
—
—
3.7e+00
2.1e+00
cases:2.81%
controls:1.21%
cases:1.40%
controls:0.40%
—
—
—
—
—
—
cases:19.05%
controls:0.57%
cases:14.83%
controls:2.03%
14
60
485
4905
7
20
494
4955
—
—
—
68
28
289
4879
31
83
178
4003
Ultrasound examination of mammary glands
HA1AE [2001303886]
HA1AE [2001303886]
2.6e+00
—
—
—
—
—
3.2e+00
cases:1.40%
controls:0.10%
—
—
—
—
—
—
—
—
—
—
cases:2.87%
controls:0.12%
7
5
492
4960
—
—
—
—
—
6
5
203
4081
Mycobacterium sp identified in Specimen by Organism specific culture
543-9 [3005702]
543-9 [3005702]
—
—
—
—
1.0e+50
3.4e+00
2.4e+00
—
—
—
—
—
—
—
—
cases:1.55%
controls:0.00%
cases:3.64%
controls:0.12%
cases:3.35%
controls:0.32%
—
—
—
—
7
0
446
4968
13
6
344
4901
7
13
202
4073
Palliative care
Z51.5 [45547323]
Z51.5 [45547323]
—
—
—
1.0e+50
—
3.2e+00
2.6e+00
—
—
—
—
—
—
cases:1.00%
controls:0.00%
—
—
cases:5.60%
controls:0.24%
cases:7.66%
controls:0.61%
—
—
—
5
0
496
4975
—
20
12
337
4895
16
25
193
4061
Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection
13956-8 [3014162]
13956-8 [3014162]
1.4e+00
—
—
—
—
3.4e+00
2.3e+00
cases:2.00%
controls:0.52%
—
—
—
—
—
—
—
—
cases:8.12%
controls:0.29%
cases:7.18%
controls:0.78%
10
26
489
4939
—
—
—
—
29
14
328
4893
15
32
194
4054
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
6.9e-01
1.0e+00
—
—
2.0e+00
1.1e+00
8.3e-01
cases:11.82%
controls:6.30%
cases:4.59%
controls:1.69%
—
—
—
—
cases:1.77%
controls:0.24%
cases:5.88%
controls:2.00%
cases:12.44%
controls:5.82%
59
313
440
4652
23
84
478
4891
—
—
8
12
445
4956
21
98
336
4809
26
238
183
3848
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
TQX10 [2001310152]
1.3e+00
1.7e+00
—
—
—
2.5e+00
3.2e+00
cases:2.00%
controls:0.56%
cases:1.20%
controls:0.22%
—
—
—
—
—
—
cases:1.68%
controls:0.14%
cases:8.13%
controls:0.37%
10
28
489
4937
6
11
495
4964
—
—
—
6
7
351
4900
17
15
192
4071
mycophenolic acid; oral, parenteral
L04AA06 [21603896]
L04AA06 [21603896]
—
—
—
—
—
2.9e+00
2.7e+00
—
—
—
—
—
—
—
—
—
—
cases:6.44%
controls:0.37%
cases:6.70%
controls:0.47%
—
—
—
—
—
23
18
334
4889
14
19
195
4067
Gas panel - Arterial blood
24336-0 [3019060]
24336-0 [3019060]
1.0e+00
6.9e-01
2.6e+00
—
—
2.0e+00
—
cases:3.21%
controls:1.15%
cases:1.00%
controls:0.50%
cases:1.60%
controls:0.12%
—
—
—
—
cases:3.08%
controls:0.43%
—
—
16
57
483
4908
5
25
496
4950
8
6
493
4969
—
—
11
21
346
4886
—
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
33762-6 [3029187]
3.3e-01
5.5e-01
1.7e+00
—
2.9e+00
1.0e+00
1.5e-01
cases:8.82%
controls:6.53%
cases:5.99%
controls:3.56%
cases:2.79%
controls:0.50%
—
—
cases:10.38%
controls:0.66%
cases:11.48%
controls:4.42%
cases:13.88%
controls:12.16%
44
324
455
4641
30
177
471
4798
14
25
487
4950
—
47
33
406
4935
41
217
316
4690
29
497
180
3589
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
1.5e+00
1.0e+00
—
—
—
2.6e+00
1.4e+00
cases:7.41%
controls:1.75%
cases:1.80%
controls:0.66%
—
—
—
—
—
—
cases:10.64%
controls:0.86%
cases:8.61%
controls:2.23%
37
87
462
4878
9
33
492
4942
—
—
—
38
42
319
4865
18
91
191
3995
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
60026-2 [40763086]
-7.9e-03
-9.9e-02
2.3e+00
1.0e+50
2.4e+00
8.2e-01
1.2e-02
cases:9.22%
controls:9.28%
cases:4.59%
controls:5.05%
cases:5.79%
controls:0.60%
cases:1.40%
controls:0.00%
cases:5.52%
controls:0.52%
cases:10.92%
controls:5.12%
cases:13.88%
controls:13.73%
46
461
453
4504
23
251
478
4724
29
30
472
4945
7
0
494
4975
25
26
428
4942
39
251
318
4656
29
561
180
3525
methylprednisolone; oral, parenteral
H02AB04 [21602732]
H02AB04 [21602732]
1.4e-01
4.8e-01
—
—
-1.0e+50
3.1e+00
2.4e+00
cases:2.20%
controls:1.91%
cases:1.20%
controls:0.74%
—
—
—
—
cases:0.00%
controls:0.16%
cases:10.92%
controls:0.53%
cases:16.75%
controls:1.81%
11
95
488
4870
6
37
495
4938
—
—
0
8
453
4960
39
26
318
4881
35
74
174
4012
General Practice Dentistry
1223G0001X [38003675]
1223G0001X [38003675]
—
—
—
—
—
3.0e+00
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.24%
cases:6.22%
controls:0.54%
—
—
—
—
—
17
12
340
4895
13
22
196
4064
Thrombin time
3243-3 [3036489]
3243-3 [3036489]
—
—
—
1.0e+50
1.0e+50
3.8e+00
1.7e+00
—
—
—
—
—
—
cases:4.59%
controls:0.00%
cases:7.06%
controls:0.00%
cases:5.88%
controls:0.14%
cases:4.31%
controls:0.78%
—
—
—
23
0
478
4975
32
0
421
4968
21
7
336
4900
9
32
200
4054
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
2885-2 [3020630]
4.0e-01
1.7e+00
—
1.0e+50
—
2.5e+00
1.1e+00
cases:2.20%
controls:1.49%
cases:4.19%
controls:0.76%
—
—
cases:7.19%
controls:0.00%
—
—
cases:8.12%
controls:0.69%
cases:6.70%
controls:2.23%
11
74
488
4891
21
38
480
4937
—
36
0
465
4975
—
29
34
328
4873
14
91
195
3995
EKG study
11524-6 [3013512]
11524-6 [3013512]
3.7e-01
3.9e-01
2.1e+00
—
2.5e+00
8.6e-01
2.3e-01
cases:11.42%
controls:8.20%
cases:6.59%
controls:4.54%
cases:4.59%
controls:0.60%
—
—
cases:7.73%
controls:0.68%
cases:12.04%
controls:5.50%
cases:15.31%
controls:12.51%
57
407
442
4558
33
226
468
4749
23
30
478
4945
—
35
34
418
4934
43
270
314
4637
32
511
177
3575
Procalcitonin [Mass/volume] in Serum or Plasma
33959-8 [3046279]
33959-8 [3046279]
1.1e+00
1.7e+00
—
1.0e+50
—
3.1e+00
2.3e+00
cases:1.40%
controls:0.46%
cases:1.20%
controls:0.22%
—
—
cases:1.40%
controls:0.00%
—
—
cases:7.56%
controls:0.37%
cases:8.13%
controls:0.88%
7
23
492
4942
6
11
495
4964
—
7
0
494
4975
—
27
18
330
4889
17
36
192
4050
Psychiatry
26 [38004469]
26 [38004469]
2.2e-01
1.6e-01
1.2e+00
—
2.2e+00
1.9e+00
1.3e+00
cases:4.41%
controls:3.59%
cases:1.80%
controls:1.53%
cases:2.00%
controls:0.58%
—
—
cases:5.30%
controls:0.60%
cases:9.24%
controls:1.49%
cases:11.48%
controls:3.52%
22
178
477
4787
9
76
492
4899
10
29
491
4946
—
24
30
429
4938
33
73
324
4834
24
144
185
3942
X-ray examination of the lungs in one projection
GD1PA [2001303645]
GD1PA [2001303645]
—
—
2.7e+00
1.0e+50
—
2.7e+00
6.9e-01
—
—
—
—
cases:1.80%
controls:0.12%
cases:1.20%
controls:0.00%
—
—
cases:7.56%
controls:0.57%
cases:3.35%
controls:1.71%
—
—
9
6
492
4969
6
0
495
4975
—
27
28
330
4879
7
70
202
4016
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
10839-9 [3021337]
5.2e-01
7.1e-01
—
1.0e+50
3.6e+00
1.7e+00
3.3e-01
cases:7.21%
controls:4.41%
cases:3.99%
controls:2.01%
—
—
cases:3.79%
controls:0.00%
cases:7.73%
controls:0.22%
cases:12.89%
controls:2.59%
cases:8.61%
controls:6.36%
36
219
463
4746
20
100
481
4875
—
19
0
482
4975
35
11
418
4957
46
127
311
4780
18
260
191
3826
Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection
40988-8 [3044254]
40988-8 [3044254]
9.2e-01
1.2e+00
—
1.0e+50
1.0e+50
3.5e+00
1.8e+00
cases:1.00%
controls:0.40%
cases:1.00%
controls:0.30%
—
—
cases:1.00%
controls:0.00%
cases:2.65%
controls:0.00%
cases:7.28%
controls:0.24%
cases:5.74%
controls:0.98%
5
20
494
4945
5
15
496
4960
—
5
0
496
4975
12
0
441
4968
26
12
331
4895
12
40
197
4046
Cells panel - Urine sediment
58434-2 [40761535]
58434-2 [40761535]
-1.6e-01
—
2.4e+00
—
2.8e+00
9.1e-01
8.5e-01
cases:2.00%
controls:2.34%
—
—
cases:1.60%
controls:0.14%
—
—
cases:1.99%
controls:0.12%
cases:2.24%
controls:0.92%
cases:3.83%
controls:1.66%
10
116
489
4849
—
8
7
493
4968
—
9
6
444
4962
8
45
349
4862
8
68
201
4018
Neutrophils [#/volume] in Blood
26499-4 [3017732]
26499-4 [3017732]
2.2e-01
4.4e-01
2.7e+00
—
—
1.5e+00
1.0e+00
cases:1.20%
controls:0.97%
cases:1.00%
controls:0.64%
cases:1.80%
controls:0.12%
—
—
—
—
cases:3.92%
controls:0.90%
cases:7.66%
controls:2.94%
6
48
493
4917
5
32
496
4943
9
6
492
4969
—
—
14
44
343
4863
16
120
193
3966
Thorax extensive CT-examination
GD1BD [2001303621]
GD1BD [2001303621]
5.8e-01
—
—
—
—
2.8e+00
2.4e+00
cases:1.00%
controls:0.56%
—
—
—
—
—
—
—
—
cases:1.96%
controls:0.12%
cases:2.39%
controls:0.22%
5
28
494
4937
—
—
—
—
7
6
350
4901
5
9
204
4077
Granulocytes [#/volume] in Blood
30394-1 [3035715]
30394-1 [3035715]
—
—
—
—
—
2.3e+00
2.8e+00
—
—
—
—
—
—
—
—
—
—
cases:1.68%
controls:0.16%
cases:2.39%
controls:0.15%
—
—
—
—
—
6
8
351
4899
5
6
204
4080
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
N05BA06 [21604571]
4.2e-01
6.6e-01
—
—
—
3.3e+00
1.8e+00
cases:1.40%
controls:0.93%
cases:1.40%
controls:0.72%
—
—
—
—
—
—
cases:14.57%
controls:0.61%
cases:6.70%
controls:1.15%
7
46
492
4919
7
36
494
4939
—
—
—
52
30
305
4877
14
47
195
4039
12 lead EKG panel
34534-8 [3044889]
34534-8 [3044889]
-1.0e-01
-1.9e-02
1.6e+00
—
2.7e+00
8.4e-01
3.5e-02
cases:18.64%
controls:20.24%
cases:10.18%
controls:10.35%
cases:6.19%
controls:1.37%
—
—
cases:15.01%
controls:1.13%
cases:21.57%
controls:10.62%
cases:25.36%
controls:24.69%
93
1005
406
3960
51
515
450
4460
31
68
470
4907
—
68
56
385
4912
77
521
280
4386
53
1009
156
3077
FEV1/FVC --post bronchodilation
69970-2 [42868459]
69970-2 [42868459]
4.7e-01
1.2e+00
—
—
—
2.4e+00
2.6e+00
cases:2.40%
controls:1.51%
cases:1.40%
controls:0.44%
—
—
—
—
—
—
cases:4.48%
controls:0.43%
cases:8.61%
controls:0.66%
12
75
487
4890
7
22
494
4953
—
—
—
16
21
341
4886
18
27
191
4059
FVC percent change Respiratory system
69982-7 [42868471]
69982-7 [42868471]
4.7e-01
1.2e+00
—
—
—
2.4e+00
2.6e+00
cases:2.40%
controls:1.51%
cases:1.40%
controls:0.44%
—
—
—
—
—
—
cases:4.48%
controls:0.43%
cases:8.61%
controls:0.66%
12
75
487
4890
7
22
494
4953
—
—
—
16
21
341
4886
18
27
191
4059
FEV1 percent change
69983-5 [42868472]
69983-5 [42868472]
4.7e-01
1.2e+00
—
—
—
2.4e+00
2.6e+00
cases:2.40%
controls:1.51%
cases:1.40%
controls:0.44%
—
—
—
—
—
—
cases:4.48%
controls:0.43%
cases:8.61%
controls:0.66%
12
75
487
4890
7
22
494
4953
—
—
—
16
21
341
4886
18
27
191
4059
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
19875-4 [3001668]
4.7e-01
1.2e+00
—
—
—
2.4e+00
2.6e+00
cases:2.40%
controls:1.51%
cases:1.40%
controls:0.44%
—
—
—
—
—
—
cases:4.48%
controls:0.43%
cases:8.61%
controls:0.66%
12
75
487
4890
7
22
494
4953
—
—
—
16
21
341
4886
18
27
191
4059
FEV1 --post bronchodilation
20155-8 [3023550]
20155-8 [3023550]
4.7e-01
1.2e+00
—
—
—
2.4e+00
2.6e+00
cases:2.40%
controls:1.51%
cases:1.40%
controls:0.44%
—
—
—
—
—
—
cases:4.48%
controls:0.43%
cases:8.61%
controls:0.66%
12
75
487
4890
7
22
494
4953
—
—
—
16
21
341
4886
18
27
191
4059
magnesium hydroxide; oral
G04BX01 [21602658]
G04BX01 [21602658]
5.8e-01
—
—
—
—
3.0e+00
2.1e+00
cases:1.00%
controls:0.56%
—
—
—
—
—
—
—
—
cases:7.28%
controls:0.41%
cases:4.31%
controls:0.56%
5
28
494
4937
—
—
—
—
26
20
331
4887
9
23
200
4063
magnesium hydroxide; oral
A02AA04 [21600052]
A02AA04 [21600052]
5.8e-01
—
—
—
—
3.0e+00
2.1e+00
cases:1.00%
controls:0.56%
—
—
—
—
—
—
—
—
cases:7.28%
controls:0.41%
cases:4.31%
controls:0.56%
5
28
494
4937
—
—
—
—
26
20
331
4887
9
23
200
4063
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
QAE10 [2001309784]
1.9e+00
—
—
—
—
—
3.0e+00
cases:1.80%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
cases:2.39%
controls:0.12%
9
13
490
4952
—
—
—
—
—
5
5
204
4081
Diffusion capacity of lung
54715006 [4182985]
54715006 [4182985]
—
—
—
—
—
2.8e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:1.68%
controls:0.10%
cases:2.39%
controls:0.29%
—
—
—
—
—
6
5
351
4902
5
12
204
4074
Toxoplasma gondii IgG Ab [Units/volume] in Serum
8039-0 [3014959]
8039-0 [3014959]
—
—
1.0e+50
1.0e+50
1.0e+50
4.9e+00
—
—
—
—
—
cases:2.59%
controls:0.00%
cases:12.57%
controls:0.00%
cases:11.92%
controls:0.00%
cases:12.32%
controls:0.10%
—
—
—
—
13
0
488
4975
63
0
438
4975
54
0
399
4968
44
5
313
4902
—
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
3.5e-01
8.5e-01
1.9e+00
—
9.9e-01
1.2e+00
5.8e-01
cases:34.27%
controls:26.91%
cases:17.76%
controls:8.44%
cases:5.59%
controls:0.84%
—
—
cases:3.09%
controls:1.17%
cases:23.53%
controls:8.48%
cases:38.28%
controls:25.84%
171
1336
328
3629
89
420
412
4555
28
42
473
4933
—
14
58
439
4910
84
416
273
4491
80
1056
129
3030
Toxoplasma gondii IgM Ab [Units/volume] in Serum
8040-8 [3027529]
8040-8 [3027529]
—
—
1.0e+50
1.0e+50
1.0e+50
4.9e+00
—
—
—
—
—
cases:2.59%
controls:0.00%
cases:12.57%
controls:0.00%
cases:11.92%
controls:0.00%
cases:12.04%
controls:0.10%
—
—
—
—
13
0
488
4975
63
0
438
4975
54
0
399
4968
43
5
314
4902
—
Sedation and analgesia
WX002 [2001310758]
WX002 [2001310758]
2.8e-03
—
2.8e+00
—
—
2.0e+00
1.1e+00
cases:2.61%
controls:2.60%
—
—
cases:1.60%
controls:0.10%
—
—
—
—
cases:4.48%
controls:0.65%
cases:5.26%
controls:1.88%
13
129
486
4836
—
8
5
493
4970
—
—
16
32
341
4875
11
77
198
4009
Neck ultrasound examination
EP1AE [2001302284]
EP1AE [2001302284]
1.8e+00
—
—
—
—
2.9e+00
1.7e+00
cases:1.40%
controls:0.24%
—
—
—
—
—
—
—
—
cases:2.24%
controls:0.12%
cases:2.39%
controls:0.44%
7
12
492
4953
—
—
—
—
8
6
349
4901
5
18
204
4068
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
2157-6 [3007220]
-1.5e-01
4.2e-01
1.6e+00
—
2.1e+00
9.6e-01
5.3e-01
cases:5.61%
controls:6.47%
cases:4.59%
controls:3.06%
cases:1.80%
controls:0.36%
—
—
cases:3.31%
controls:0.42%
cases:7.84%
controls:3.16%
cases:13.88%
controls:8.66%
28
321
471
4644
23
152
478
4823
9
18
492
4957
—
15
21
438
4947
28
155
329
4752
29
354
180
3732
prednisolone; oral, parenteral
H02AB06 [21602734]
H02AB06 [21602734]
3.5e-01
7.6e-01
9.3e-01
—
1.8e+00
1.3e+00
7.5e-01
cases:15.63%
controls:11.54%
cases:10.78%
controls:5.37%
cases:2.59%
controls:1.05%
—
—
cases:5.08%
controls:0.89%
cases:20.45%
controls:6.32%
cases:22.49%
controls:12.09%
78
573
421
4392
54
267
447
4708
13
52
488
4923
—
23
44
430
4924
73
310
284
4597
47
494
162
3592
Oral Surgery
19 [38004464]
19 [38004464]
—
—
—
—
—
2.9e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:4.48%
controls:0.26%
cases:3.83%
controls:0.69%
—
—
—
—
—
16
13
341
4894
8
28
201
4058
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
3.4e-01
7.5e-01
9.3e-01
—
1.8e+00
1.3e+00
7.4e-01
cases:15.63%
controls:11.60%
cases:10.78%
controls:5.41%
cases:2.59%
controls:1.05%
—
—
cases:5.08%
controls:0.89%
cases:20.45%
controls:6.36%
cases:22.49%
controls:12.11%
78
576
421
4389
54
269
447
4706
13
52
488
4923
—
23
44
430
4924
73
312
284
4595
47
495
162
3591
Flexible bronchoscopy
UGC12 [2001303610]
UGC12 [2001303610]
1.2e+00
—
1.0e+50
—
1.0e+50
2.7e+00
1.9e+00
cases:2.00%
controls:0.60%
—
—
cases:1.00%
controls:0.00%
—
—
cases:1.32%
controls:0.00%
cases:3.64%
controls:0.24%
cases:3.83%
controls:0.61%
10
30
489
4935
—
5
0
496
4975
—
6
0
447
4968
13
12
344
4895
8
25
201
4061
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
JN1AE [2001305517]
5.4e-01
—
—
—
—
2.5e+00
2.0e+00
cases:1.20%
controls:0.70%
—
—
—
—
—
—
—
—
cases:2.24%
controls:0.18%
cases:5.26%
controls:0.71%
6
35
493
4930
—
—
—
—
8
9
349
4898
11
29
198
4057
Ultrasound examination of lower leg veins
PH2AE [2001309451]
PH2AE [2001309451]
2.4e-01
—
—
—
—
3.1e+00
1.4e+00
cases:1.80%
controls:1.43%
—
—
—
—
—
—
—
—
cases:7.28%
controls:0.35%
cases:6.70%
controls:1.71%
9
71
490
4894
—
—
—
—
26
17
331
4890
14
70
195
4016
CD4 cells/Lymphocytes in Specimen
80223-1 [21494815]
80223-1 [21494815]
—
—
—
—
—
—
4.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.96%
controls:0.15%
—
—
—
—
—
—
25
6
184
4080
Extensive abdominal CT
JN3BD [2001305556]
JN3BD [2001305556]
9.5e-01
—
—
—
—
2.8e+00
1.7e+00
cases:2.61%
controls:1.03%
—
—
—
—
—
—
—
—
cases:2.52%
controls:0.16%
cases:3.35%
controls:0.61%
13
51
486
4914
—
—
—
—
9
8
348
4899
7
25
202
4061
tinzaparin; parenteral
B01AB10 [21600981]
B01AB10 [21600981]
1.5e+00
—
—
—
—
3.0e+00
6.2e-01
cases:1.80%
controls:0.40%
—
—
—
—
—
—
—
—
cases:4.20%
controls:0.22%
cases:2.87%
controls:1.57%
9
20
490
4945
—
—
—
—
15
11
342
4896
6
64
203
4022
Clinic/Center
261Q00000X [38004207]
261Q00000X [38004207]
1.3e+00
—
—
—
1.0e+50
3.1e+00
—
cases:2.20%
controls:0.58%
—
—
—
—
—
—
cases:1.32%
controls:0.00%
cases:4.48%
controls:0.20%
—
—
11
29
488
4936
—
—
—
6
0
447
4968
16
10
341
4897
—
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 [36031861]
95941-1 [36031861]
—
—
—
1.0e+50
—
3.1e+00
1.4e+00
—
—
—
—
—
—
cases:1.00%
controls:0.00%
—
—
cases:10.36%
controls:0.53%
cases:7.66%
controls:2.06%
—
—
—
5
0
496
4975
—
37
26
320
4881
16
84
193
4002
Base excess in Venous blood by calculation
1927-3 [3002032]
1927-3 [3002032]
-1.6e-01
3.9e-01
1.7e+00
—
2.8e+00
1.6e+00
4.2e-01
cases:1.20%
controls:1.41%
cases:1.80%
controls:1.23%
cases:1.00%
controls:0.18%
—
—
cases:3.97%
controls:0.24%
cases:5.32%
controls:1.16%
cases:5.26%
controls:3.52%
6
70
493
4895
9
61
492
4914
5
9
496
4966
—
18
12
435
4956
19
57
338
4850
11
144
198
3942
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
1960-4 [3008152]
1.0e+00
—
2.4e+00
1.0e+50
—
2.0e+00
6.6e-01
cases:2.61%
controls:0.97%
—
—
cases:1.80%
controls:0.16%
cases:1.00%
controls:0.00%
—
—
cases:4.20%
controls:0.61%
cases:3.35%
controls:1.76%
13
48
486
4917
—
9
8
492
4967
5
0
496
4975
—
15
30
342
4877
7
72
202
4014
CD3+CD4+ (T4 helper) cells [#/volume] in Blood
24467-3 [3028167]
24467-3 [3028167]
—
—
—
—
—
—
4.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.53%
controls:0.15%
—
—
—
—
—
—
22
6
187
4080
pH of Venous blood
2746-6 [3012544]
2746-6 [3012544]
-7.5e-02
3.7e-01
1.7e+00
—
2.8e+00
1.6e+00
3.6e-01
cases:1.40%
controls:1.51%
cases:1.80%
controls:1.25%
cases:1.00%
controls:0.18%
—
—
cases:3.97%
controls:0.26%
cases:5.60%
controls:1.20%
cases:5.26%
controls:3.72%
7
75
492
4890
9
62
492
4913
5
9
496
4966
—
18
13
435
4955
20
59
337
4848
11
152
198
3934
testosterone; oral, parenteral, rectal, sublingual, transdermal
G03BA03 [21602510]
G03BA03 [21602510]
—
—
-1.0e+50
—
-1.0e+50
2.3e+00
2.0e+00
—
—
—
—
cases:0.00%
controls:0.18%
—
—
cases:0.00%
controls:0.22%
cases:5.32%
controls:0.57%
cases:6.22%
controls:0.86%
—
—
0
9
501
4966
—
0
11
453
4957
19
28
338
4879
13
35
196
4051
Chronic apical periodontitis
K04.5 [45586691]
K04.5 [45586691]
2.0e-01
1.2e-01
1.9e+00
—
2.5e+00
1.8e+00
7.0e-01
cases:4.81%
controls:3.97%
cases:1.40%
controls:1.25%
cases:1.20%
controls:0.18%
—
—
cases:1.77%
controls:0.14%
cases:5.88%
controls:1.06%
cases:9.09%
controls:4.72%
24
197
475
4768
7
62
494
4913
6
9
495
4966
—
8
7
445
4961
21
52
336
4855
19
193
190
3893
mercaptopurine
L01BB02 [21601428]
L01BB02 [21601428]
—
2.3e+00
—
—
—
4.3e+00
—
—
—
cases:1.00%
controls:0.10%
—
—
—
—
—
—
cases:7.00%
controls:0.10%
—
—
—
5
5
496
4970
—
—
—
25
5
332
4902
—
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
2021-4 [3021447]
-1.3e-01
4.0e-01
1.8e+00
—
2.8e+00
1.4e+00
4.4e-01
cases:1.20%
controls:1.37%
cases:1.80%
controls:1.21%
cases:1.00%
controls:0.16%
—
—
cases:3.97%
controls:0.24%
cases:4.76%
controls:1.16%
cases:5.74%
controls:3.77%
6
68
493
4897
9
60
492
4915
5
8
496
4967
—
18
12
435
4956
17
57
340
4850
12
154
197
3932
Rhinovirus RNA [Presence] in Specimen by NAA with probe detection
7993-9 [3025023]
7993-9 [3025023]
2.1e+00
—
1.0e+50
1.0e+50
1.0e+50
—
4.3e+00
cases:1.00%
controls:0.12%
—
—
cases:1.00%
controls:0.00%
cases:1.40%
controls:0.00%
cases:5.52%
controls:0.00%
—
—
cases:8.13%
controls:0.12%
5
6
494
4959
—
5
0
496
4975
7
0
494
4975
25
0
428
4968
—
17
5
192
4081
Enterovirus RNA [Presence] in Specimen by NAA with probe detection
29591-5 [3016881]
29591-5 [3016881]
1.8e+00
—
1.0e+50
1.0e+50
1.0e+50
—
4.3e+00
cases:1.00%
controls:0.16%
—
—
cases:1.00%
controls:0.00%
cases:1.40%
controls:0.00%
cases:5.52%
controls:0.00%
—
—
cases:8.13%
controls:0.12%
5
8
494
4957
—
5
0
496
4975
7
0
494
4975
25
0
428
4968
—
17
5
192
4081
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
FB1BD [2001302407]
1.0e+00
—
1.0e+50
—
—
2.3e+00
1.9e+00
cases:2.00%
controls:0.75%
—
—
cases:1.60%
controls:0.00%
—
—
—
—
cases:3.36%
controls:0.35%
cases:4.31%
controls:0.64%
10
37
489
4928
—
8
0
493
4975
—
—
12
17
345
4890
9
26
200
4060
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
6.2e-01
1.1e+00
1.3e+00
—
1.2e+00
1.4e+00
1.2e+00
cases:10.22%
controls:5.78%
cases:6.39%
controls:2.29%
cases:1.40%
controls:0.40%
—
—
cases:1.32%
controls:0.40%
cases:8.40%
controls:2.28%
cases:17.22%
controls:6.12%
51
287
448
4678
32
114
469
4861
7
20
494
4955
—
6
20
447
4948
30
112
327
4795
36
250
173
3836
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
30313-1 [3002173]
8.2e-01
5.1e-01
2.3e+00
—
—
1.9e+00
6.3e-01
cases:2.61%
controls:1.17%
cases:1.00%
controls:0.60%
cases:2.20%
controls:0.22%
—
—
—
—
cases:4.76%
controls:0.75%
cases:4.78%
controls:2.62%
13
58
486
4907
5
30
496
4945
11
11
490
4964
—
—
17
37
340
4870
10
107
199
3979
Specific gravity of Urine by Refractometry
5810-7 [3019150]
5810-7 [3019150]
-1.9e-01
-4.2e-01
2.2e+00
—
2.0e+00
6.5e-01
-2.6e-01
cases:4.61%
controls:5.52%
cases:2.20%
controls:3.30%
cases:3.19%
controls:0.38%
—
—
cases:3.31%
controls:0.44%
cases:6.16%
controls:3.32%
cases:7.18%
controls:9.15%
23
274
476
4691
11
164
490
4811
16
19
485
4956
—
15
22
438
4946
22
163
335
4744
15
374
194
3712
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
2.6e-01
4.5e-01
6.4e-01
—
1.2e+00
1.6e+00
8.9e-01
cases:21.64%
controls:17.60%
cases:15.77%
controls:10.69%
cases:5.19%
controls:2.81%
—
—
cases:7.28%
controls:2.36%
cases:38.94%
controls:10.92%
cases:38.28%
controls:20.26%
108
874
391
4091
79
532
422
4443
26
140
475
4835
—
33
117
420
4851
139
536
218
4371
80
828
129
3258
CD3-CD16+CD56+ (Natural killer) cells [#/volume] in Blood
9728-7 [3025271]
9728-7 [3025271]
—
—
—
—
—
1.0e+50
4.2e+00
—
—
—
—
—
—
—
—
—
—
cases:6.72%
controls:0.00%
cases:8.61%
controls:0.15%
—
—
—
—
—
24
0
333
4907
18
6
191
4080
dexamethasone and antiinfectives
S02CA06 [21605178]
S02CA06 [21605178]
8.2e-01
-1.0e+50
—
—
—
2.6e+00
1.5e+00
cases:1.80%
controls:0.81%
cases:0.00%
controls:0.20%
—
—
—
—
—
—
cases:5.04%
controls:0.39%
cases:6.70%
controls:1.52%
9
40
490
4925
0
10
501
4965
—
—
—
18
19
339
4888
14
62
195
4024
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
216
39
95.48
307.65
6.1
1.3
—
—
—
0
0
163
52
45.64
261.36
1.6
1.5
141.90
152.66
au/ml
0.25
41
19
160
58
39.77
246.31
12.8
6.1
436.03
819.33
iu/ml
—
29
6
152
49
43.80
242.28
4.4
3.9
629.62
490.25
u/ml
—
13
8
305
422
16.54
237.69
24.6
2.1
346.70
234.19
u/l
4.82
299
398
147
62
32.93
213.89
1.4
1.3
250.56
201.38
u/ml
0.51
88
29
152
98
21.69
183.99
4.6
1.3
—
—
—
0
0
103
34
37.73
160.94
12.5
2.5
0.78
0.57
%
0.40
98
28
251
422
10.76
160.58
8.3
2.2
60.14
65.94
e9/l
1.14
208
330
205
268
12.13
159.78
3.2
2.1
9.97
11.27
g/l
3.22
200
251
139
99
18.94
158.99
1.7
1.6
—
—
—
0
0
138
97
19.15
158.94
4.3
1.4
—
—
—
0
0
116
63
23.55
150.82
4.9
1.3
—
—
—
0
0
175
217
11.77
140.48
1.5
1.3
1.14
1.19
g/l
0.21
169
207
84
33
30.29
123.25
5.4
1.3
—
—
—
0
0
79
28
33.21
119.87
1.9
1.0
—
—
—
0
0
84
36
27.75
119.37
5.5
1.3
—
—
—
0
0
154
204
10.39
116.17
1.7
1.7
1.52
1.53
g/l
0.06
136
179
247
571
7.46
112.92
15.6
5.1
1.09
1.03
mmol/l
2.96
242
512
94
0
+∞
101.53
1.0
0.0
—
—
—
0
0
72
34
24.50
98.12
1.2
1.0
—
—
—
0
0
242
634
6.37
94.57
4.9
1.9
29.00
29.78
s
1.12
237
612
93
88
12.71
88.15
2.2
1.4
—
—
—
0
0
234
633
5.99
87.19
13.0
2.9
0.80
0.83
mmol/l
3.12
226
586
172
357
6.77
84.93
2.3
1.5
65.79
66.81
g/l
0.87
167
325
67
39
19.63
83.08
4.7
2.4
—
—
—
0
0
155
296
7.09
83.01
4.0
1.5
—
—
—
0
0
302
1075
5.45
80.05
11.5
2.5
309.07
356.33
umol/l
7.29
293
914
66
43
17.49
77.34
2.4
1.4
—
—
—
0
0
68
47
16.54
77.28
2.6
1.3
—
—
—
0
0
79
75
12.28
74.35
2.0
1.3
—
—
—
0
0
56
30
20.85
71.90
1.8
1.4
—
—
—
0
0
58
34
19.12
71.46
6.1
1.1
—
—
—
0
0
58
34
19.12
71.46
6.1
1.1
—
—
—
0
0
58
34
19.12
71.46
6.1
1.1
—
—
—
0
0
70
5
161.86
67.81
1.3
1.0
—
—
—
0
0
233
768
4.75
65.33
5.5
1.9
—
—
—
0
0
45
20
24.59
62.23
1.4
1.6
—
—
—
0
0
45
20
24.59
62.23
1.4
1.6
—
—
—
0
0
44
19
25.25
61.50
7.3
1.1
—
—
—
0
0
44
19
25.25
61.50
7.3
1.1
—
—
—
0
0
44
19
25.25
61.50
7.2
1.1
—
—
—
0
0
44
19
25.25
61.50
7.3
1.1
—
—
—
0
0
82
106
9.03
61.31
1.5
2.2
28.91
12.01
mg/l
1.36
66
99
242
855
4.49
61.19
3.4
1.7
3.86
1.29
mg/l
3.53
219
664
67
71
10.72
58.14
1.3
1.2
191.66
16.89
u/l
4.43
61
62
89
135
7.78
58.03
2.5
1.2
—
—
—
0
0
66
78
9.57
52.73
2.4
1.3
—
—
—
0
0
60
63
10.66
52.28
2.4
1.4
—
—
—
0
0
38
17
24.08
52.25
1.4
1.1
—
—
—
0
0
180
583
4.23
49.64
3.7
1.8
—
—
—
0
0
83
139
6.94
49.13
3.5
3.6
—
—
—
0
0
203
742
3.89
46.73
1.5
1.3
2.42
2.72
g/l
1.59
180
435
36
19
20.31
46.14
2.3
1.8
40.24
47.24
%
0.71
17
11
169
551
4.09
45.72
3.7
1.9
—
—
—
0
0
45
51
9.58
36.84
5.9
1.9
33.24
33.16
pg
0.04
45
51
135
435
3.86
36.29
16.5
2.4
8.14
8.70
umol/l
0.10
130
378
42
9
50.72
35.28
8.8
2.7
1.24
1.22
%
—
42
9
347
2010
3.28
34.86
34.4
4.0
11.43
12.37
umol/l
1.06
342
1895
208
906
3.19
34.42
17.5
2.0
—
—
—
0
0
313
1724
3.12
34.06
18.4
2.4
—
—
estimate
—
0
0
42
12
38.00
33.34
7.4
1.1
—
—
—
0
0
42
12
38.00
33.34
7.4
1.2
—
—
—
0
0
42
12
38.00
33.34
7.4
1.1
—
—
—
0
0
353
2114
3.19
32.49
59.9
6.4
3.22
4.33
e9/l
2.10
335
1820
311
1806
2.86
28.96
18.7
3.9
32.39
35.43
g/l
15.88
302
1669
335
2036
2.89
28.35
30.2
5.6
0.11
0.20
e9/l
23.51
301
1764
55
107
5.64
27.56
3.9
1.2
—
—
—
0
0
37
48
8.23
27.13
5.1
1.1
—
—
—
0
0
37
48
8.23
27.13
5.1
1.1
—
—
—
0
0
37
48
8.23
27.13
5.1
1.1
—
—
—
0
0
316
1897
2.76
26.80
19.4
5.8
1.20
1.21
mmol/l
2.61
306
1713
60
133
4.98
25.95
1.3
1.2
30.38
48.96
mg/l
3.53
51
115
56
117
5.25
25.92
1.3
1.2
1.36
1.41
ratio
0.12
38
72
338
2138
2.73
25.16
23.7
6.2
1.20
1.21
mmol/l
1.35
296
1845
34
44
8.21
24.95
5.4
1.1
—
—
—
0
0
34
45
8.02
24.48
5.4
1.1
—
—
—
0
0
34
45
8.02
24.48
5.4
1.1
—
—
—
0
0
58
133
4.79
24.06
1.3
1.2
26.54
35.72
mg/l
1.59
50
116
30
9
35.30
23.60
2.9
1.3
—
—
—
0
0
30
9
35.30
23.60
2.9
1.3
—
—
—
0
0
32
13
26.16
23.34
1.1
1.3
—
—
—
0
0
32
16
21.25
21.97
2.8
1.3
—
—
—
0
0
32
16
21.25
21.97
2.8
1.3
—
—
—
0
0
66
180
4.06
21.88
7.8
1.6
—
—
—
0
0
40
72
5.94
21.67
2.0
1.3
—
—
—
0
0
60
167
3.94
19.29
3.6
1.5
—
—
—
0
0
143
670
2.58
18.85
1.9
2.5
2.01
2.25
g/l
6.26
137
614
83
293
3.19
18.55
3.7
1.6
—
—
—
0
0
220
1259
2.32
18.52
6.7
2.7
29.38
34.33
u/l
1.50
212
1185
133
614
2.58
17.98
1.9
2.6
36.20
23.07
%
9.21
126
567
22
7
32.75
17.16
2.0
1.1
—
—
—
0
0
39
85
4.89
17.10
1.6
1.7
—
—
—
0
0
23
11
21.82
16.11
2.8
2.3
—
—
—
0
0
23
33
7.25
15.38
2.6
1.3
—
—
—
0
0
26
44
6.17
14.93
3.0
1.7
2.50
10463.90
u/l
—
6
9
35
79
4.68
14.71
1.1
1.3
74.09
302.02
miu/ml
—
7
26
338
2436
2.15
14.67
14.1
4.7
6.81
6.78
mmol/l
0.11
333
2320
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
46
130
3.79
14.41
3.3
2.9
0.31
0.40
iu/ml
0.75
21
74
19
7
28.11
14.37
1.2
1.1
—
—
—
0
0
66
242
2.98
13.68
1.7
1.5
—
—
—
0
0
197
1186
2.08
13.63
2.3
2.3
2.94
2.86
mg/l
0.16
166
1009
293
2046
2.02
13.29
15.6
18.3
1.28
1.34
inr
1.36
272
1724
271
1846
2.00
13.14
4.3
3.0
711.23
125.71
ug/l
7.01
260
1709
36
96
3.96
12.22
1.1
1.3
—
—
—
0
0
48
158
3.25
11.92
1.2
1.3
0.20
0.42
g/l
0.49
43
138
155
904
2.03
11.32
4.5
4.4
65.92
359.66
ng/l
2.83
127
761
40
123
3.44
11.06
1.3
1.3
0.00
0.00
g/l
-0.00
40
116
197
1275
1.89
10.44
4.0
2.3
47.61
61.55
u/l
2.91
184
1172
53
205
2.77
9.92
4.3
1.4
3.10
2.70
ug/l
0.29
40
151
205
1372
1.83
9.58
5.7
2.1
2.30
2.35
mmol/l
5.08
187
1183
19
22
8.93
9.36
3.7
1.3
—
—
—
0
0
18
20
9.29
9.09
2.3
2.6
1620.56
704.15
u/ml
1.32
18
20
73
345
2.30
8.98
1.8
2.1
0.21
0.20
g/l
0.36
65
315
12
5
24.51
8.94
8.7
1.6
2.08
3.60
%
—
12
5
107
594
2.01
8.73
12.6
6.2
104.75
104.27
mmol/l
0.58
107
594
117
679
1.94
8.37
4.7
3.0
2.67
2.56
e6/l
0.04
64
334
8
0
+∞
8.35
11.0
0.0
—
—
—
0
0
28
82
3.56
8.34
1.6
1.3
—
—
—
0
0
28
82
3.56
8.34
1.6
1.3
—
—
—
0
0
201
1385
1.75
8.21
5.1
3.2
49.48
122.32
e6/l
0.75
161
1067
143
896
1.83
8.04
2.0
1.8
1265.36
1153.08
nmol/l
0.71
127
679
17
23
7.61
7.73
2.6
1.2
—
—
—
0
0
103
1649
0.53
7.65
3.0
1.9
1.68
1.30
mmol/l
4.66
95
1376
29
93
3.25
7.53
2.7
1.3
35.37
1440.53
e6/l
0.67
24
79
16
21
7.83
7.44
2.7
1.3
—
—
—
0
0
331
3877
0.58
7.40
5.3
6.3
2.52
2.59
mmol/l
0.68
309
3557
15
18
8.55
7.36
2.8
1.3
—
—
—
0
0
28
92
3.16
7.00
2.8
1.2
13.17
63.36
e6/l
0.46
23
77
27
87
3.22
6.96
2.3
1.3
3.72
3.98
mmol/l
0.72
27
82
57
272
2.23
6.83
6.8
4.3
1.06
2.15
mmol/l
1.90
48
196
172
1186
1.68
6.73
5.0
3.1
0.65
0.44
e6/l
0.33
133
873
267
2065
1.62
6.56
2.4
2.3
90.55
95.67
pmol/l
1.04
203
1046
318
3725
0.61
6.45
5.9
7.2
39.26
40.21
mmol/mol
1.37
299
3456
326
2655
1.63
6.42
7.0
4.9
222.00
3576.53
e6/l
1.42
11
47
29
103
2.93
6.37
2.7
1.2
498.72
522.99
mg/l
0.10
29
96
205
1510
1.60
6.02
3.1
3.4
1171.24
1638.19
ng/l
1.88
193
1301
83
487
1.84
5.62
5.0
3.6
2.05
1.94
mmol/l
0.09
71
425
327
3766
0.63
5.53
4.9
5.3
1.25
1.45
mmol/l
14.30
302
3442
114
747
1.68
5.25
4.8
2.9
1.73
1.18
e6/l
0.40
64
405
5
0
+∞
5.21
1.2
0.0
—
—
—
0
0
5
0
+∞
5.21
7.8
0.0
—
—
—
0
0
5
0
+∞
5.21
3.4
0.0
8.42
—
ng/l
—
5
0
11
16
7.00
4.97
1.6
1.3
—
—
—
0
0
63
353
1.90
4.92
2.3
2.0
80.34
34.25
u/l
0.47
56
287
186
1393
1.53
4.84
2.1
1.8
18.96
20.05
nmol/l
0.48
178
1181
8
7
11.58
4.80
3.0
1.0
—
—
—
0
0
380
4198
0.63
4.76
103.5
23.3
106.90
134.78
g/l
94.25
375
4129
380
4196
0.63
4.71
103.1
23.1
156.10
242.23
e9/l
35.36
373
4086
380
4196
0.63
4.71
103.5
23.6
32.33
40.18
%
79.84
375
4126
380
4196
0.63
4.71
102.9
23.1
3.59
4.46
e12/l
65.13
372
4070
380
4194
0.63
4.66
102.8
23.0
93.68
91.45
fl
10.19
375
4125
335
3797
0.66
4.66
5.4
5.4
4.21
4.48
mmol/l
4.60
315
3494
15
36
4.26
4.55
1.1
1.0
—
—
—
0
0
85
536
1.70
4.48
7.9
6.9
1.32
1.25
mmol/l
0.06
67
441
26
111
2.41
4.06
1.3
1.4
—
—
—
0
0
7
7
10.12
4.02
1.0
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
10
20
5.08
3.70
1.3
1.3
—
—
—
0
0
342
3810
0.69
3.69
7.1
5.5
6.04
6.06
mmol/l
0.09
320
3445
8
12
6.75
3.68
1.3
1.2
—
—
—
0
0
14
40
3.57
3.63
1.1
1.3
—
—
—
0
0
378
4130
0.67
3.62
80.7
20.4
80.68
81.98
umol/l
0.37
371
4063
324
3632
0.70
3.48
5.6
5.3
2.06
1.95
mu/l
0.58
303
3301
10
22
4.61
3.44
1.1
1.0
—
—
—
0
0
10
22
4.61
3.44
1.3
1.2
—
—
—
0
0
7
10
7.08
3.37
1.0
1.3
—
—
—
0
0
20
83
2.47
3.34
3.0
1.2
14.52
23.77
iu/l
1.03
15
71
331
3681
0.71
3.22
55.5
14.7
78.22
76.06
ml/min/173m2
1.07
316
3404
8
15
5.40
3.20
1.0
1.3
—
—
—
0
0
8
15
5.40
3.20
1.1
1.0
—
—
—
0
0
118
1555
0.69
3.19
3.5
4.2
6.68
7.85
mg/mmol
0.17
79
991
121
1585
0.69
3.16
2.7
3.4
6.96
7.43
mmol/l
0.60
111
1341
13
44
3.01
3.15
4.0
4.3
—
—
—
0
0
23
106
2.23
3.07
6.7
5.0
1.31
1.70
mg/l
2.28
23
93
16
62
2.63
3.07
1.1
1.4
—
—
—
0
0
5
5
10.08
2.98
1.0
1.6
—
—
—
0
0
374
4057
0.71
2.92
50.1
10.4
26.84
25.04
u/l
1.52
365
3896
59
381
1.62
2.86
3.2
2.4
0.67
0.35
e6/l
0.35
59
360
12
40
3.05
2.71
1.2
1.2
1.60
1.54
u/ml
—
5
13
22
108
2.08
2.55
5.8
3.4
5.45
1.39
index
0.70
16
51
328
3606
0.75
2.52
5.8
4.5
1.53
1.26
mmol/l
7.48
307
3257
208
1750
1.32
2.39
4.0
4.2
31.48
91.76
ng/l
1.03
168
1317
334
3006
1.32
2.33
6.4
4.4
24.08
12.36
mm/h
14.53
319
2757
9
28
3.25
2.31
1.1
2.1
17.12
15.44
umol/l
—
9
23
6
13
4.66
2.27
1.2
1.2
—
—
—
0
0
6
13
4.66
2.27
1.2
1.2
—
—
—
0
0
7
18
3.93
2.26
12.6
3.1
0.71
1.06
index
—
7
18
23
121
1.94
2.24
1.4
1.3
—
—
—
0
0
10
35
2.89
2.22
1.1
1.2
—
—
—
0
0
10
35
2.89
2.22
1.1
1.2
—
—
—
0
0
245
2124
1.30
2.21
4.3
2.7
—
—
—
0
0
376
4029
0.74
2.18
75.8
19.5
3.99
4.00
mmol/l
0.41
371
3932
278
2455
1.29
2.16
4.6
3.2
69.32
48.09
u/l
2.22
264
2268
10
37
2.74
2.08
1.1
1.2
—
—
—
0
0
10
37
2.74
2.08
1.1
1.2
—
—
—
0
0
20
104
1.96
2.03
1.8
1.7
—
—
—
0
0
377
4027
0.75
2.02
67.1
19.4
138.75
139.74
mmol/l
11.14
371
3937
169
1415
1.29
1.94
3.1
2.3
113.10
282.09
u/l
2.31
159
1322
7
22
3.21
1.88
1.3
1.0
—
—
—
0
0
11
46
2.42
1.86
1.2
1.2
3.17
4.74
u/ml
—
6
19
11
46
2.42
1.86
1.6
1.2
—
—
—
0
0
5
12
4.20
1.82
1.0
1.2
—
—
—
0
0
65
870
0.71
1.82
1.3
1.3
0.79
1.33
u/ml
1.09
16
240
16
80
2.03
1.82
2.4
1.7
421.64
16.58
u/ml
0.47
16
59
17
89
1.94
1.72
1.3
1.3
—
—
—
0
0
5
13
3.87
1.72
1.2
1.3
—
—
—
0
0
5
13
3.87
1.72
1.0
1.2
—
—
—
0
0
21
119
1.80
1.68
1.4
1.5
16957.21
12982.80
e6/l
0.24
14
81
21
120
1.78
1.64
1.3
1.2
—
—
—
0
0
10
42
2.41
1.62
1.1
1.1
—
—
—
0
0
21
121
1.77
1.61
1.3
1.2
—
—
—
0
0
36
240
1.54
1.60
5.0
3.2
24.47
25.31
mmol/l
0.66
36
233
7
26
2.72
1.58
1.3
1.2
14.00
10.19
u/l
—
7
21
275
3012
0.81
1.56
4.7
4.1
14.74
14.98
pmol/l
0.78
254
2722
16
280
0.56
1.51
1.9
2.1
—
—
—
0
0
9
38
2.39
1.46
4.6
2.0
3.89
100.68
u/ml
—
9
38
70
892
0.75
1.44
3.1
2.9
0.74
0.78
ug/l
0.19
43
597
120
997
1.27
1.43
1.7
1.8
120388797.15
21906369.76
pmol/l
0.38
103
808
10
46
2.20
1.40
1.1
1.2
—
—
—
0
0
6
23
2.63
1.37
1.0
1.3
—
—
—
0
0
69
537
1.33
1.35
1.4
1.5
—
—
—
0
0
0
37
0.00
1.35
0.0
1.6
—
59.53
—
0
30
27
176
1.56
1.34
1.4
1.3
—
—
—
0
0
6
131
0.45
1.30
2.5
2.0
74.83
41.93
nmol/l
—
6
123
5
18
2.79
1.29
5.2
1.1
—
—
—
0
0
15
252
0.58
1.25
1.9
2.0
—
—
—
0
0
10
49
2.06
1.22
1.5
1.2
2250.90
1778.81
e6/l
—
10
32
18
110
1.66
1.17
1.2
1.2
—
—
—
0
0
0
34
0.00
1.16
0.0
1.6
—
0.99
—
0
22
0
34
0.00
1.16
0.0
1.6
—
1.01
—
0
22
0
34
0.00
1.16
0.0
1.6
—
1.14
—
0
22
107
1253
0.82
1.10
4.0
4.1
19.36
24.31
%
2.38
47
602
19
121
1.59
1.07
3.0
3.7
0.87
0.85
nmol/l
0.06
12
102
7
33
2.14
1.06
1.0
1.1
—
—
—
0
0
7
33
2.14
1.06
13.0
2.9
16.86
12.11
index
—
7
18
35
255
1.40
1.06
5.8
3.9
44.50
45.90
%
0.12
35
250
10
178
0.55
1.05
1.2
1.0
—
—
—
0
0
5
107
0.46
1.02
2.8
2.1
186.20
231.35
pmol/l
—
5
100
9
50
1.81
0.97
1.1
1.1
—
1.10
—
0
8
234
2149
1.16
0.95
4.7
4.1
21.56
0.00
estimate
0.49
57
440
6
29
2.08
0.89
1.0
1.0
—
—
—
0
0
6
30
2.01
0.87
1.0
1.1
—
—
—
0
0
235
2172
1.15
0.85
4.7
4.1
0.02
0.01
estimate
0.14
51
426
229
2114
1.15
0.84
4.7
4.1
0.00
0.00
estimate
-0.00
55
429
20
140
1.45
0.78
1.4
1.5
1.29
1.14
g/l
1.03
20
134
24
322
0.73
0.75
1.6
1.5
—
—
—
0
0
7
39
1.81
0.72
1.0
1.1
—
—
—
0
0
7
40
1.76
0.71
1.3
1.1
—
—
—
0
0
52
429
1.24
0.70
2.3
2.6
3.96
7.56
ug/l
1.92
45
369
7
41
1.72
0.70
1.0
1.1
—
—
—
0
0
9
58
1.56
0.70
2.1
2.3
11.08
10.67
mmol/l
—
9
58
7
42
1.68
0.68
1.0
1.1
—
—
—
0
0
49
404
1.24
0.67
6.9
3.3
—
—
—
0
0
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
143
1556
0.89
0.57
4.4
4.4
1.88
2.08
ug/l
0.50
131
1386
25
318
0.78
0.57
6.6
2.3
56.00
63.47
ml/min/173m2
0.64
11
139
124
1127
1.13
0.56
4.0
3.5
0.00
0.00
estimate
-0.00
40
338
9
62
1.46
0.53
3.9
2.2
1.19
1.19
mmol/l
—
9
62
9
64
1.41
0.51
3.9
2.2
106.33
105.30
mmol/l
—
9
64
60
522
1.17
0.50
3.2
5.3
28.10
32.51
%
2.46
48
327
17
128
1.34
0.48
1.2
1.2
—
26.78
—
0
6
23
182
1.28
0.47
1.3
1.9
4.30
7.75
iu/ml
—
7
45
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
8.70
—
0
15
0
16
0.00
0.41
0.0
1.2
—
8.31
—
0
16
8
59
1.36
0.41
1.1
1.5
—
—
—
0
0
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
229.09
—
0
11
129
1201
1.10
0.39
4.4
4.2
0.00
0.00
estimate
-0.00
49
395
47
416
1.14
0.34
1.5
1.4
—
—
—
0
0
94
1010
0.91
0.31
4.3
4.4
1.02
1.02
kg/l
0.13
80
659
94
876
1.09
0.29
3.0
2.2
2.44
2.45
mmol/l
0.17
84
762
8
66
1.22
0.27
1.8
3.0
40.54
10.13
pmol/l
—
8
66
13
105
1.24
0.25
1.4
1.3
260.00
315.58
ug/g
—
8
64
378
3843
0.94
0.24
80.5
15.3
34.40
25.44
mg/l
5.39
365
3144
72
670
1.09
0.24
1.2
1.3
1.27
11.49
u/ml
4.46
21
246
26
229
1.14
0.22
5.3
3.6
1.02
1.02
ratio
0.20
26
213
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
13
0.00
0.21
0.0
2.9
—
16.42
—
0
13
28
254
1.11
0.16
5.2
2.7
1.30
1.15
%
0.63
28
254
11
129
0.85
0.15
2.0
2.3
—
—
—
0
0
24
217
1.11
0.15
1.1
1.2
68.17
110.66
u/ml
—
6
87
49
519
0.94
0.13
13.4
7.6
—
—
—
0
0
27
250
1.08
0.11
2.9
2.7
0.71
0.63
%
1.07
27
250
165
1614
1.03
0.11
4.3
4.1
0.00
0.03
estimate
1.22
49
344
6
74
0.81
0.07
1.8
1.5
—
—
—
0
0
7
80
0.87
0.07
2.0
1.4
—
—
—
0
0
10
110
0.91
0.05
1.7
2.2
—
—
—
0
0
191
1890
1.02
0.05
3.0
2.5
75.66
78.08
nmol/l
0.60
177
1666
39
402
0.97
0.04
1.5
1.7
1.53
1.53
%
0.01
32
345
73
727
1.00
0.00
1.2
1.3
17.85
32.82
iu/ml
2.56
26
224
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
9.6
—
5.36
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
8
83
0.96
-0.00
1.8
1.7
324.38
306.50
mu/l
—
8
78
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.3
—
—
—
0
0
10
100
1.00
-0.00
2.5
2.4
30.30
36.45
umol/l
—
10
89
0
7
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
0.50
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: HLP_C3_AML – Acute myeloid leukaemia, helper endpoint
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).